BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7. [PMID: 10235156 DOI: 10.1001/jama.281.17.1623] [Cited by in Crossref: 1187] [Cited by in F6Publishing: 1136] [Article Influence: 51.6] [Reference Citation Analysis]
Number Citing Articles
1 Kato T, Hikichi T, Nakamura J, Hashimoto M, Kobashi R, Yanagita T, Suzuki R, Sugimoto M, Sato Y, Irie H, Takasumi M, Oka Y, Takagi T, Hashimoto Y, Kobayakawa M, Ohira H. Association between Submucosal Fibrosis and Endoscopic Submucosal Dissection of Recurrent Esophageal Squamous Cell Cancers after Chemoradiotherapy. Cancers 2022;14:4685. [DOI: 10.3390/cancers14194685] [Reference Citation Analysis]
2 Ren LH, Zhu Y, Chen R, Shrestha Sachin M, Lu Q, Xie WH, Lu T, Wei XY, Shi RH. Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma. World J Gastrointest Oncol 2022; 14(9): 1758-1770 [DOI: 10.4251/wjgo.v14.i9.1758] [Reference Citation Analysis]
3 Xia Y, Lin M, Huang J, Fan L. Cardiovascular disease related death among patients with esophagus cancer: A population-based competing risk analysis. Front Oncol 2022;12:976711. [DOI: 10.3389/fonc.2022.976711] [Reference Citation Analysis]
4 Zhang X, Tao S, Liang S, Chen S, Liu F, Jiang W, Chen M. Nomogram based on circulating lymphocyte subsets for predicting radiation pneumonia in esophageal squamous cell carcinoma. Front Immunol 2022;13:938795. [DOI: 10.3389/fimmu.2022.938795] [Reference Citation Analysis]
5 De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, Vernerey D. Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer? Cancers (Basel) 2022;14:4043. [PMID: 36011035 DOI: 10.3390/cancers14164043] [Reference Citation Analysis]
6 Boustani J, Créhange G. [Dose-escalated radiotherapy in esophageal cancer: A review of the literature]. Cancer Radiother 2022:S1278-3218(22)00127-5. [PMID: 36008261 DOI: 10.1016/j.canrad.2022.06.021] [Reference Citation Analysis]
7 Solidum JGN, Rojo RD, Wo JY, Dee EC. Proton Beam Therapy for Esophageal Cancer. Cancers (Basel) 2022;14:4045. [PMID: 36011037 DOI: 10.3390/cancers14164045] [Reference Citation Analysis]
8 Zheng YH, Zhao EH. Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction. World J Gastroenterol 2022; 28(31): 4299-4309 [DOI: 10.3748/wjg.v28.i31.4299] [Reference Citation Analysis]
9 Zhang X, Fang X, Liu P, Liu D, Yang H, Zhao W, Su F, Zhao K. Treatment outcomes of 156 patients with cervical esophageal cancers treated with definitive radiation therapy- A single-institution experience of a rare cancer. Front Oncol 2022;12:929583. [DOI: 10.3389/fonc.2022.929583] [Reference Citation Analysis]
10 Wu J, Deng R, Ni T, Zhong Q, Tang F, Li Y, Zhang Y. Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis. Front Oncol 2022;12:887525. [DOI: 10.3389/fonc.2022.887525] [Reference Citation Analysis]
11 Zhu H, Liu Q, Xu H, Mo M, Wang Z, Lu K, Zhou J, Chen J, Zheng X, Ye J, Ge X, Luo H, Liu Q, Deng J, Ai D, Hao S, Zhang J, Tseng IH, Song S, Chen Y, Zhao K. Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12). Radiat Oncol 2022;17:134. [PMID: 35906623 DOI: 10.1186/s13014-022-02099-y] [Reference Citation Analysis]
12 Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang Q, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh C, Mummudi N, Joshi A, Ferri L, Wong RK, O’callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong F, Chao Y, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol 2022;12:917961. [DOI: 10.3389/fonc.2022.917961] [Reference Citation Analysis]
13 Jingu K, Takahashi N, Umezawa R, Yamamoto T, Takeda K, Suzuki Y, Kishida K, Omata S, Sato Y, Harada H, Harigai A. The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis. Esophagus 2022. [PMID: 35779138 DOI: 10.1007/s10388-022-00938-1] [Reference Citation Analysis]
14 Li H, Fang Y, Gu D, Du M, Zhang Z, Sun L, Zhou G, Ye J. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial. Radiat Oncol 2022;17:105. [PMID: 35681233 DOI: 10.1186/s13014-022-02078-3] [Reference Citation Analysis]
15 Kurosaki T, Hoshino I, Kuwayama N, Isozaki T, Gunji H, Tonooka T, Soda H, Takiguchi N, Nabeya Y, Takayama W. Primary esophageal cancer treated by esophagectomy with distal pancreatectomy: a report of three cases. Clin J Gastroenterol 2022. [PMID: 35661087 DOI: 10.1007/s12328-022-01646-0] [Reference Citation Analysis]
16 Zhang P, Hou X, Cai B, Yu W, Chen J, Huang X, Li Y, Zeng M, Ren Z, Gabriel E, Qu B, Liu F. Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world. Ann Transl Med 2022;10:708. [PMID: 35845479 DOI: 10.21037/atm-22-2779] [Reference Citation Analysis]
17 Sun J, Huang W, Chen J, Zhang Y. Association of 3D-CRT and IMRT accelerated hyperfractionated radiotherapy with local control rate and 5-year survival in esophageal squamous cell carcinoma patients. Br J Radiol 2022;95:20211195. [PMID: 35119916 DOI: 10.1259/bjr.20211195] [Reference Citation Analysis]
18 Harris JA, Ottaviani G, Treister NS, Hanna GJ. An Overview of Clinical Oncology and Impact on Oral Health. Front Oral Health 2022;3:874332. [DOI: 10.3389/froh.2022.874332] [Reference Citation Analysis]
19 Zhang W, Xie Q, Zhu B, Wang X, He L, Zhang Y. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study. Medicine (Baltimore) 2022;101:e29166. [PMID: 35482986 DOI: 10.1097/MD.0000000000029166] [Reference Citation Analysis]
20 Yu Y, Wu H, Qiu J, Ke D, Wu Y, Lin M, Zheng Q, Zheng H, Wang Z, Li H, Liu L, Li J, Yao Q. The novel pretreatment immune prognostic index discriminates survival outcomes in locally advanced non-operative esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: a 6-year retrospective study. Transl Oncol 2022;21:101430. [PMID: 35452997 DOI: 10.1016/j.tranon.2022.101430] [Reference Citation Analysis]
21 Li LQ, Fu QG, Zhao WD, Wang YD, Meng WW, Su TS. Chemoradiotherapy Versus Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma: The Role of Definitive Radiotherapy for Primary Tumor in the Metastatic Setting. Front Oncol 2022;12:824206. [PMID: 35433478 DOI: 10.3389/fonc.2022.824206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Yang YX, Zheng YZ, Gao TT, Liu SL, Xi M, Liu MZ, Wang JY, Qi SN, Yang Y, Zhao L. Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. Cancer Med 2022. [PMID: 35434962 DOI: 10.1002/cam4.4751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang S, Zhang C, Wang Y, Luo K, Yang Y, Yang Y, Liu S, Li Q, Xi M. Risk factors and prognosis for esophageal fistula in patients with esophageal squamous cell carcinoma during radiotherapy. Esophagus 2022. [PMID: 35419642 DOI: 10.1007/s10388-022-00919-4] [Reference Citation Analysis]
24 An D, Cao Q, Su N, Li W, Li Z, Liu Y, Zhang Y, Li B. Response Prediction to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Delta-Radiomics Based on Sequential Whole-Tumor ADC Map. Front Oncol 2022;12:787489. [PMID: 35392222 DOI: 10.3389/fonc.2022.787489] [Reference Citation Analysis]
25 Fernández-Montes A, Alcaide J, Alsina M, Custodio AB, Franco LF, Gallego Plazas J, Gómez-Martín C, Richart P, Rivera F, Martin-Richard M. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol 2022;24:658-69. [PMID: 35347573 DOI: 10.1007/s12094-022-02801-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li F, Li Y, Wang X, Zhang Y, Liu X, Liu S, Wang W, Wang J, Guo Y, Xu M, Li J. Inter-Observer and Intra-Observer Variability in Gross Tumor Volume Delineation of Primary Esophageal Carcinomas Based on Different Combinations of Diagnostic Multimodal Images. Front Oncol 2022;12:817413. [DOI: 10.3389/fonc.2022.817413] [Reference Citation Analysis]
27 Kumar D, Dey T, Khosla D, Gedela S, Oinam AS, Kapoor R. Comparative analyses of paclitaxel/carboplatin with cisplatin/5-fluorouracil-based chemoradiation in locally advanced inoperable upper and middle third esophageal cancer: A randomized prospective pilot study. J Cancer Res Ther 2022;18:747-53. [PMID: 35900549 DOI: 10.4103/jcrt.jcrt_100_21] [Reference Citation Analysis]
28 Dong X, Deng W, Jiang L, Yang D, Yu H, Li D, Shi A, Yu R, Wang W. A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma. Radiation Medicine and Protection 2022. [DOI: 10.1016/j.radmp.2022.04.002] [Reference Citation Analysis]
29 Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li Z. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer 2022;10:e004291. [PMID: 35338088 DOI: 10.1136/jitc-2021-004291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
30 Lu J, Wang Y, Lan M, Lv J, Li T, Wu L, Wang Q, Lang J, Wang F. Pretreatment Low Serum Sodium as a Prognostic Factor for Patients with Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/4586729] [Reference Citation Analysis]
31 Zhu H, Lu X, Jiang J, Lu J, Sun X, Zuo Y. Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma. Dose-Response 2022;20:155932582210767. [DOI: 10.1177/15593258221076720] [Reference Citation Analysis]
32 Wang X, Hu B, Chen J, Xie F, Han D, Zhao Q, Sun H, Fu C, Liu C, Wang Z, Lin H, Huang W. Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site. BMC Cancer 2022;22:207. [PMID: 35209855 DOI: 10.1186/s12885-022-09319-4] [Reference Citation Analysis]
33 Fokas E, Martin D, Rödel C. [Radiotherapy dose escalation does not improve local control in patients with esophageal cancer after definitive radiochemotherapy: the ARTDECO randomized phase III trial]. Strahlenther Onkol 2022. [PMID: 35166870 DOI: 10.1007/s00066-022-01906-5] [Reference Citation Analysis]
34 Yang Y, Chen M, Xie J, Ji Y, Sheng L, Qiu G, Du X, Wei Q. Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer. Front Oncol 2022;12:778898. [DOI: 10.3389/fonc.2022.778898] [Reference Citation Analysis]
35 Dong J, Wang GD, Wang HZ. Clinical analysis of patients with respiratory failure after esophageal cancer operation. Transl Cancer Res 2021;10:5238-45. [PMID: 35116373 DOI: 10.21037/tcr-21-1505] [Reference Citation Analysis]
36 Rogers JE, D Silva MS, Waters RE, Ajani JA. Esophageal cancer: emerging therapeutics. Expert Opin Ther Targets 2022. [PMID: 35119973 DOI: 10.1080/14728222.2022.2036718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
37 Lohan-Codeço M, Barambo-Wagner ML, Nasciutti LE, Ribeiro Pinto LF, Meireles Da Costa N, Palumbo A Jr. Molecular mechanisms associated with chemoresistance in esophageal cancer. Cell Mol Life Sci 2022;79:116. [PMID: 35113247 DOI: 10.1007/s00018-022-04131-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu Z, Zhao W, Lin Q, Yang H, Zheng X, Zhou J, Huang G, Li L, Li J, Zhang Z, Zhou G, Gu D, Du M, Mo M, Jia H, Zhang Z, Zhao K. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. JAMA Netw Open 2022;5:e220120. [PMID: 35188552 DOI: 10.1001/jamanetworkopen.2022.0120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
39 Mori Y, Kikuchi O, Horimatsu T, Hara H, Hironaka S, Kojima T, Kato K, Tsushima T, Ishihara R, Mukai K, Uozumi R, Tada H, Kasai H, Kawaguchi A, Muto M. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus 2022. [PMID: 35050435 DOI: 10.1007/s10388-021-00905-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yan C, Ma X, Guo Z, Wei X, Han D, Zhang T, Chen X, Cao F, Dong J, Zhao G, Gao X, Wang T, Jiang Y, Wang P, Pang Q, Zhang W. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. Oncoimmunology 2022;11:2025668. [PMID: 35036077 DOI: 10.1080/2162402X.2022.2025668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Cellini F, Manfrida S, Casà C, Romano A, Arcelli A, Zamagni A, De Luca V, Colloca GF, D'Aviero A, Fuccio L, Lancellotta V, Tagliaferri L, Boldrini L, Mattiucci GC, Gambacorta MA, Morganti AG, Valentini V. Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers (Basel) 2022;14:431. [PMID: 35053594 DOI: 10.3390/cancers14020431] [Reference Citation Analysis]
42 Alves IPF, Tercioti Junior V, Coelho Neto JS, Ferrer JAP, Carvalheira JBC, Pereira EB, Lopes LR, Andreollo NA. NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE. Arq Bras Cir Dig 2022;34:e1621. [PMID: 35019133 DOI: 10.1590/0102-672020210002e1621] [Reference Citation Analysis]
43 Li Y, Du Q, Wei X, Guo Z, Lei T, Li Y, Han D, Wu X, Zhang K, Zhang T, Chen X, Dong J, Zhang B, Wei H, Zhang W, Pang Q, Wang P. A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis. Front Oncol 2021;11:703074. [PMID: 34912702 DOI: 10.3389/fonc.2021.703074] [Reference Citation Analysis]
44 Guo S, Liu F, Liu H, Wu Y, Zhang X, Ye W, Luo G, Li Q, Chen N, Hu N, Wang B, Zhang J, Lin M, Feng H, Qiu B. A Prospective Phase II Study of Simultaneous Modulated Accelerated Radiotherapy Concurrently With CDDP/S1 for Esophageal Squamous Cell Carcinoma in the Elderly. Front Oncol 2021;11:760631. [PMID: 34900709 DOI: 10.3389/fonc.2021.760631] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Chen C, Chen J, Luo T, Wang S, Guo H, Zeng C, Wu Y, Liu W, Huang R, Zhai T, Chen Z, Li D. Late Toxicities, Failure Patterns, Local Tumor Control, and Survival of Esophageal Squamous Cell Carcinoma Patients After Chemoradiotherapy With a Simultaneous Integrated Boost: A 5-Year Phase II Study. Front Oncol 2021;11:738936. [PMID: 34868933 DOI: 10.3389/fonc.2021.738936] [Reference Citation Analysis]
46 van Eerden RAG, van Doorn L, de Man FM, Heersche N, Doukas M, van den Bosch TPP, Oomen-de Hoop E, de Bruijn P, Bins S, Ibrahim E, Nikkessen S, Friberg LE, Koolen SLW, Spaander MCW, Mathijssen RHJ. Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. Front Pharmacol 2021;12:759146. [PMID: 34858183 DOI: 10.3389/fphar.2021.759146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Favareto SL, Sousa CF, Pinto PJ, Ramos H, Chen MJ, Castro DG, Silva ML, Gondim G, Pellizzon ACA, Fogaroli RC. Clinical Prognostic Factors for Patients With Esophageal Cancer Treated With Definitive Chemoradiotherapy. Cureus 2021;13:e18894. [PMID: 34820218 DOI: 10.7759/cureus.18894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. World J Gastrointest Oncol 2021; 13(11): 1781-1790 [PMID: 34853650 DOI: 10.4251/wjgo.v13.i11.1781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Shi Y, Ge X, Ju M, Zhang Y, Di X, Liang L. Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma - Mini Review. Cancer Manag Res 2021;13:8355-65. [PMID: 34764697 DOI: 10.2147/CMAR.S337489] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
50 Wu H, Yu Y, Zheng Q, Liu T, Wu Y, Wang Z, Zheng H, Liu L, Li J. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021;16:207. [PMID: 34717670 DOI: 10.1186/s13014-021-01931-1] [Reference Citation Analysis]
51 Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer 2021. [PMID: 34675397 DOI: 10.1038/s41416-021-01485-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
52 Lu Y, Xu C, Wang H, Song T, Wu S, Liang X, Xu H. Long-Term Survival Outcomes and Comparison of Different Treatment Modalities for Stage I-III Cervical Esophageal Carcinoma. Front Med (Lausanne) 2021;8:714619. [PMID: 34631736 DOI: 10.3389/fmed.2021.714619] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Ishiyama K, Oguma J, Kubo K, Kanematsu K, Kurita D, Daiko H. Salvage minimally invasive esophagectomy after definitive chemoradiotherapy for esophageal cancer can improve postoperative complications compared with salvage open esophagectomy. Surg Endosc 2021. [PMID: 34642795 DOI: 10.1007/s00464-021-08672-y] [Reference Citation Analysis]
54 Sumiya T, Ishikawa H, Hiroshima Y, Nakamura M, Murakami M, Mizumoto M, Okumura T, Sakurai H. The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients. J Radiat Res 2021:rrab094. [PMID: 34632514 DOI: 10.1093/jrr/rrab094] [Reference Citation Analysis]
55 Shi Z, Zhu X, Ke S, Qiu H, Cai G, Zhangcai Y, Chen Y. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. Radiother Oncol 2021;164:236-44. [PMID: 34627936 DOI: 10.1016/j.radonc.2021.09.033] [Reference Citation Analysis]
56 Booka E, Kikuchi H, Hiramatsu Y, Takeuchi H. The Impact of Infectious Complications after Esophagectomy for Esophageal Cancer on Cancer Prognosis and Treatment Strategy. J Clin Med 2021;10:4614. [PMID: 34640631 DOI: 10.3390/jcm10194614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Zhang W, Yan C, Zhang T, Chen X, Dong J, Zhao J, Han D, Wang J, Zhao G, Cao F, Zhou D, Jiang H, Tang P, Zhao L, Yuan Z, Wang Q, Wang P, Pang Q. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology 2021;10:1971418. [PMID: 34616588 DOI: 10.1080/2162402X.2021.1971418] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
58 Wang P, Wang X, Xu L, Yu J, Teng F. Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI. Cancer Sci 2021. [PMID: 34618997 DOI: 10.1111/cas.15156] [Reference Citation Analysis]
59 Sun D, Chen Q, Gai Z, Zhang F, Yang X, Hu W, Chen C, Yang G, Hörmann S, Kullak-Ublick GA, Visentin M. The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin. Front Pharmacol 2021;12:684545. [PMID: 34603016 DOI: 10.3389/fphar.2021.684545] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Liu A, Wang Y, Wang X, Zhu L, Nie Y, Li M. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients. Radiat Oncol 2021;16:195. [PMID: 34600574 DOI: 10.1186/s13014-021-01921-3] [Reference Citation Analysis]
61 Wang J, Xiao L, Wang S, Pang Q, Wang J. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:665231. [PMID: 34589418 DOI: 10.3389/fonc.2021.665231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Imamura H, Tamura S, Hattori H, Kidogami S, Mokutani Y, Kishimoto T, Hashimoto Y, Hirose H, Yoshioka S, Kuwayama M, Endo S, Sasaki Y. Coexisting primary tumors from esophageal cancer and myelodysplastic syndromes: A case report. Clin Case Rep 2021;9:e04872. [PMID: 34584722 DOI: 10.1002/ccr3.4872] [Reference Citation Analysis]
63 Imai T, Tanaka Y, Ojio H, Sato Y, Suetsugu T, Fukada M, Yasufuku I, Iwata Y, Imai H, Okumura N, Matsuhashi N, Takahashi T, Noguchi K, Miyazaki T, Yoshida K. Successful treatment of cervical and upper thoracic esophageal adenocarcinoma using induction chemotherapy followed by surgery: a case report. Int Cancer Conf J 2021;10:334-40. [PMID: 34567948 DOI: 10.1007/s13691-021-00505-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bhattacharyya T, Harilal V, Sashidharan R, Mallick I, Arunsingh M, Chakraborty S, Achari RB, Chatterjee S. Real-world results of definitive chemoradiation in carcinoma oesophagus: can SCOPE1 results be replicated outside trial setting? Ecancermedicalscience 2021;15:1280. [PMID: 34567265 DOI: 10.3332/ecancer.2021.1280] [Reference Citation Analysis]
65 Xin N, Wei R, Huang K, Chen Z, Liu C, Fang Y, Xu Z, Ding X, Tang H. Comparative study on short-term efficacy of single incision plus one (SI+1) port and multiportal 3D laparoscopic minimally invasive esophagectomy. J Gastrointest Oncol 2021;12:1277-84. [PMID: 34532087 DOI: 10.21037/jgo-21-441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Cai P, Yang Y, Li DJ. Efficacy and Prognostic Analysis of 315 Stage I-IVa Esophageal Cancer Patients Treated with Simultaneous Integrated Boost-Intensity-Modulated Radiation Therapy. Cancer Manag Res 2021;13:6969-75. [PMID: 34522139 DOI: 10.2147/CMAR.S329625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Tang P, Tan C, Pang Q, Chi CW, Wang Y, Yuan Z, Huang YC, Chen YJ. Combination of 35-Gene Mutation Profile and Radiotherapy Dosimetry Predicts the Therapeutic Outcome of Definitive Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. Front Oncol 2021;11:729418. [PMID: 34513706 DOI: 10.3389/fonc.2021.729418] [Reference Citation Analysis]
68 Vošmik M, Kopecký J, John S, Kubeček O, Lochman P, Banni AM, Hruška L, Sirák I. Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers (Basel) 2021;13:4591. [PMID: 34572818 DOI: 10.3390/cancers13184591] [Reference Citation Analysis]
69 Takahashi N, Umezawa R, Kishida K, Yamamoto T, Ishikawa Y, Takeda K, Suzuki Y, Kawabata K, Teramura S, Jingu K. Clinical outcomes and prognostic factors for esophageal cancer in patients aged 80 years or older who were treated with definitive radiotherapy and chemoradiotherapy. Esophagus 2021. [PMID: 34476633 DOI: 10.1007/s10388-021-00876-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
70 Suwa T, Ishida Y, Negoro Y, Kusumi F, Kadokawa Y, Aizawa R, Nakajima T, Okamoto Y, Okuno Y, Yamada K, Ogura M, Murakami M, Mizowaki T. Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma. Clin Transl Radiat Oncol 2021;30:88-94. [PMID: 34430719 DOI: 10.1016/j.ctro.2021.08.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02706-1. [PMID: 34454045 DOI: 10.1016/j.ijrobp.2021.08.018] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, Abe T, Nakamura T, Okada M, Toh Y, Shibuya Y, Yamamoto S, Katayama H, Nakamura K, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 2021:S0016-5085(21)03352-7. [PMID: 34389340 DOI: 10.1053/j.gastro.2021.08.007] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
73 Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, Xu G, Bu S, Song B, Xie K, Huang S, Zheng Y, Sheng L, Lai X, Chen Y, Cheng L, Hu X, Ji W, Fang M, Kong Y, Yu X, Li H, Li R, Shi L, Shen W, Zhu C, Lv J, Huang R, He H, Chen M. Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol 2021. [PMID: 34351356 DOI: 10.1001/jamaoncol.2021.2705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
74 Zlotnik O, Goshen-Lago T, Haddad R, Brenner B, Kundel Y, Ben-Aharon I, Kashtan H. Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer. Cancer Rep (Hoboken) 2021;:e1489. [PMID: 34350714 DOI: 10.1002/cnr2.1489] [Reference Citation Analysis]
75 Eads JR, Haller DG. Primary Chemoradiotherapy for Older Patients With Esophageal Cancer. JAMA Oncol 2021. [PMID: 34351378 DOI: 10.1001/jamaoncol.2021.2668] [Reference Citation Analysis]
76 Peng D, He J, Liu H, Cao J, Wang Y, Chen Y. FAPI PET/CT research progress in digestive system tumours. Dig Liver Dis 2021:S1590-8658(21)00380-7. [PMID: 34364808 DOI: 10.1016/j.dld.2021.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
77 Gong H, Li B. Guidelines for Radiotherapy of Esophageal Carcinoma (2020 Edition): Branch of Radiation Oncology Therapists, Chinese Medical Association; Society of Radiation Oncology Therapy, Chinese Medical Association; Cancer Radiotherapy Committee of China Anti‐Cancer Association. Prec Radiat Oncol 2021;5:54-72. [DOI: 10.1002/pro6.1119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Yu R, Wang W, Li T, Li J, Zhao K, Wang W, Liang L, Wu H, Ai T, Huang W, Li L, Yu W, Wei C, Wang Y, Shen W, Xiao Z. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol 2021. [PMID: 34269067 DOI: 10.2217/fon-2021-0632] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
79 Chow R, Lock M, Lee SL, Lo SS, Simone CB 2nd. Esophageal Cancer Radiotherapy Dose Escalation Meta Regression Commentary: "High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis". Front Oncol 2021;11:700300. [PMID: 34336689 DOI: 10.3389/fonc.2021.700300] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Ogawa K, Ishikawa H, Hisakura K, Hiroshima Y, Moriwaki T, Yamada T, Yamamoto Y, Akashi Y, Owada Y, Ohara Y, Enomoto T, Furuya K, Doi M, Shimomura O, Takahashi K, Hashimoto S, Sakurai H, Oda T. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma. Int J Clin Oncol 2021. [PMID: 34241725 DOI: 10.1007/s10147-021-01981-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Li X, Gao H, Zhu J, Huang Y, Zhu Y, Huang W, Li Z, Sun K, Liu Z, Tian J, Li B. 3D Deep Learning Model for the Pretreatment Evaluation of Treatment Response in Esophageal Carcinoma: A Prospective Study (ChiCTR2000039279). Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)00825-7. [PMID: 34229050 DOI: 10.1016/j.ijrobp.2021.06.033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Zhang X, Ai D, Wang J, Chen Y, Liu Q, Deng J, Yang H, Nie Y, Chen W, Zhao W, Zhao K. The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial. Front Oncol 2021;11:669575. [PMID: 34295813 DOI: 10.3389/fonc.2021.669575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Vlacich G, Ballard A, Badiyan SN, Spraker M, Henke L, Kim H, Lockhart AC, Park H, Suresh R, Huang Y, Robinson CG, Bradley JD, Samson PP. A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. Clin Transl Radiat Oncol 2021;30:19-25. [PMID: 34278011 DOI: 10.1016/j.ctro.2021.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, Cai L, Hu Y, Qiu B, Zhang L, Shen J, Yang Y, Liu M, Xi M. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun 2021;12:4014. [PMID: 34188053 DOI: 10.1038/s41467-021-24288-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
85 Suh YG, Bayasgalan U, Kim HT, Lee JM, Kim MS, Lee Y, Lee DY, Lee SU, Kim TH, Moon SH. Photon Versus Proton Beam Therapy for T1-3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis. Front Oncol 2021;11:699172. [PMID: 34235087 DOI: 10.3389/fonc.2021.699172] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Xiao Z. Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Front Oncol 2021;11:618776. [PMID: 34235073 DOI: 10.3389/fonc.2021.618776] [Reference Citation Analysis]
87 Chang X, Deng W, Wang X, Zhou Z, Yang J, Guo W, Liu M, Qi X, Li L, Zhang K, Zhang M, Shi Y, Liu K, Zhao Y, Wang H, Yu Z, Zhang J, Wang L, Qiao X, Han C, Zhu S, Zhang R, Chen J, Hu C, Zhang F, Hou X, Pang Q, Zhang W, Li G, Lin H, Sun X, Ge X, Li C, Ge H, Li D, Wang Y, Lu N, Gao X, Qin S, Tian Y, Xiao Z. Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. Radiat Oncol 2021;16:102. [PMID: 34107984 DOI: 10.1186/s13014-020-01691-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen MJC, Jeene PM, Reinders JG, van Berge Henegouwen MI, Thano A, van Hooft JE, van Laarhoven HWM, van der Gaast A. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol 2021;39:2816-24. [PMID: 34101496 DOI: 10.1200/JCO.20.03697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
89 Wang SX, Marshall MB. Chemoradiation Therapy as Definitive Treatment of Esophageal Cancer. Surg Clin North Am 2021;101:443-51. [PMID: 34048764 DOI: 10.1016/j.suc.2021.03.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
90 Watkins AA, Zerillo JA, Kent MS. Trimodality Approach for Esophageal Malignancies. Surg Clin North Am 2021;101:453-65. [PMID: 34048765 DOI: 10.1016/j.suc.2021.03.007] [Reference Citation Analysis]
91 Fabian T. Management of Postoperative Complications After Esophageal Resection. Surg Clin North Am 2021;101:525-39. [PMID: 34048771 DOI: 10.1016/j.suc.2021.03.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Fajardo R, Abbas AE, Petrov RV, Bakhos CT. Salvage Esophagectomy. Surg Clin North Am 2021;101:467-82. [PMID: 34048766 DOI: 10.1016/j.suc.2021.03.008] [Reference Citation Analysis]
93 Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, Wang Y, Jiang Y, Wang Q, Zhang B, Qian D, Wang J, Zhou D, Ren X, Yu Z, Zhao L, Yuan Z, Wang P, Pang Q. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. Oncologist 2021;26:e1110-24. [PMID: 33893689 DOI: 10.1002/onco.13797] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
94 Fan B, Li C, Mu F, Qin W, Wang L, Sun X, Wang C, Zou B, Wang S, Li W, Hu M. Dose escalation guided by 18F-FDG PET/CT for esophageal cancer. Radiation Medicine and Protection 2021;2:55-60. [DOI: 10.1016/j.radmp.2021.04.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
95 Wang L, Wang X, Ren X, Han C, Xiao Z, Zhu S, Qiao X, Zhou Z, Shen W, Chen J, Pang Q, Zhang W, Zhao Y, Wang X, Sun X, Ge X, Zhang K, Hu M, Li G, Liu M, Wang Y. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A). Transl Cancer Res 2021;10:2932-43. [PMID: 35116602 DOI: 10.21037/tcr-21-505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Gao HM, Shen WB, Xu JR, Li YM, Li SG, Zhu SC. Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer. Int J Clin Oncol 2021;26:1640-9. [PMID: 34043101 DOI: 10.1007/s10147-021-01943-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
97 Zhou XL, Yu CH, Wang WW, Ji FZ, Xiong YZ, Zhu WG, Tong YS. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021;16:94. [PMID: 34039375 DOI: 10.1186/s13014-021-01821-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Xu L, Chen J, Guo H, Huang R, Guo L, Yu Y 2nd, Zhai T, Wu F, Chen Z, Li D, Chen C. Distribution of Peripheral Blood Cells in Esophageal Cancer Patients During Concurrent Chemoradiotherapy Predicts Long-Term Locoregional Progression Hazard After Treatment (GASTO1072). Cancer Manag Res 2021;13:4203-15. [PMID: 34079373 DOI: 10.2147/CMAR.S307695] [Reference Citation Analysis]
99 Zeng J, Cui X, Cheng L, Chen Y, Du X, Sheng L. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Cancer Radiother 2021;25:441-6. [PMID: 33958272 DOI: 10.1016/j.canrad.2021.01.008] [Reference Citation Analysis]
100 Li C, Wang X, Wang L, Chen J, Zhang W, Pang Q, Zhao Y, Sun X, Zhang K, Li G, Li L, Qiao X, Liu M, Wang Y, Deng L, Wang W, Bi N, Zhang T, Deng W, Ni W, Chang X, Han W, Zhou Z, Liang J, Feng Q, Wang L, Chen D, Lv J, Zhu S, Han C, Xiao Z. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncol 2021;60:627-34. [PMID: 33793382 DOI: 10.1080/0284186X.2021.1902564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
101 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
102 Yura M, Koyanagi K, Hara A, Hayashi K, Tajima Y, Kaneko Y, Fujisaki H, Hirata A, Takano K, Hongo K, Yo K, Yoneyama K, Tamai Y, Dehari R, Nakagawa M. Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report. World J Clin Cases 2021; 9(12): 2801-2810 [PMID: 33969062 DOI: 10.12998/wjcc.v9.i12.2801] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Khin NS, Tan SH, Wang ML, Siow TR, Lim FL, Wang FQ, Ng MC, Lam JY, Yip C. Chemoradiation-induced changes in systemic inflammatory markers and their prognostic significance in oesophageal squamous cell carcinoma. Br J Radiol 2021;94:20200314. [PMID: 33861156 DOI: 10.1259/bjr.20200314] [Reference Citation Analysis]
104 Zhang Y, Feng W, Gao LT, Cai XW, Liu Q, Zhu ZF, Fu XL, Yu W. Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma. Radiother Oncol 2021;159:190-6. [PMID: 33812913 DOI: 10.1016/j.radonc.2021.03.031] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
105 Shiraishi O, Yasuda T, Kato H, Momose K, Hiraki Y, Yasuda A, Shinkai M, Kimura Y, Imano M. Comparison of Aggressive Planned Salvage Surgery Versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 33768398 DOI: 10.1245/s10434-021-09875-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Wang J, Li B; Chinese Association for Therapeutic Radiation Oncologists, China Society for Radiation Oncology, Chinese Association of Radiation Therapy. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition). Prec Radiat Oncol 2021;5:4-11. [DOI: 10.1002/pro6.1107] [Reference Citation Analysis]
107 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
108 Pöttgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH, Lax H, Stuschke M. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Radiat Oncol 2021;16:59. [PMID: 33757534 DOI: 10.1186/s13014-021-01788-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Ho YC, Lai YC, Lin HY, Ko MH, Wang SH, Yang SJ, Lin PJ, Chou TW, Hung LC, Huang CC, Chang TH, Lin JB, Lin JC. Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy. Sci Rep 2021;11:6644. [PMID: 33758232 DOI: 10.1038/s41598-021-86019-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
110 Ino A, Sakanaka K, Inoo H, Ishida Y, Kanda J, Mizowaki T. Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation. Int Cancer Conf J 2021;10:201-6. [PMID: 34221832 DOI: 10.1007/s13691-021-00479-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Yeom JG, Kim JH, Kim JW, Cho Y, Lee IJ, Lee CG, Chun J, Youn YH, Park H. Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:1255. [PMID: 33809157 DOI: 10.3390/cancers13061255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Wang JL, Ma R, Kong W, Zhao R, Wang YY. Lymphopenia in Esophageal Cancer: What Have We Learned? Front Oncol 2021;11:625963. [PMID: 33791213 DOI: 10.3389/fonc.2021.625963] [Reference Citation Analysis]
113 Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, Xi M, Hu Y, Zhu Y, Li Q. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother Oncol 2021;158:191-9. [PMID: 33667583 DOI: 10.1016/j.radonc.2021.02.031] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
114 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
115 Zheng ZY, Yang PL, Luo W, Yu SX, Xu HY, Huang Y, Li RY, Chen Y, Xu XE, Liao LD, Wang SH, Huang HC, Li EM, Xu LY. STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:901. [PMID: 33670049 DOI: 10.3390/cancers13040901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
116 Zhao L, Chen S, Chen S, Pang Y, Dai Y, Hu S, Lin L, Fu L, Sun L, Wu H, Chen H, Lin Q. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol 2021;158:55-61. [PMID: 33621587 DOI: 10.1016/j.radonc.2021.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
117 Yang X, Wang L, Du H, Lin B, Yi J, Wen X, Geng L, Du X. Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. Medicine (Baltimore) 2021;100:e24328. [PMID: 33546064 DOI: 10.1097/MD.0000000000024328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 de Pascale S, Parise P, Valmasoni M, Weindelmayer J, Terraneo F, Cella CA, Giacopuzzi S, Cossu A, Massaron S, Elmore U, Merigliano S, Fumagalli Romario U, On Behalf Of The Italian Society For The Study Of Esophageal Diseases Sisme. Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. Cancers (Basel) 2021;13:666. [PMID: 33562316 DOI: 10.3390/cancers13040666] [Reference Citation Analysis]
119 Wang C, Tong J, Tang M, Lu Y, Liang G, Zhang Z, Chen T. Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus. Cancer Manag Res 2021;13:1075-85. [PMID: 33574705 DOI: 10.2147/CMAR.S294344] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
120 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
121 Lu J, Zhang C, Yang X, Yao XJ, Zhang Q, Sun XC. Synthesis and Preliminary Evaluation of a Novel 18F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging. Front Oncol 2020;10:572097. [PMID: 33604284 DOI: 10.3389/fonc.2020.572097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Wang P, Yang M, Wang X, Zhao Z, Li M, Yu J. A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy. Ann Transl Med 2021;9:233. [PMID: 33708860 DOI: 10.21037/atm-20-1460] [Reference Citation Analysis]
123 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
124 Wang WP, Ma J, Lu Q, Han Y, Li XF, Jiang T, Zhao JB. Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma. Turk J Gastroenterol 2020;31:948-54. [PMID: 33626010 DOI: 10.5152/tjg.2020.19757] [Reference Citation Analysis]
125 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
126 Zeng C, Zhai T, Chen J, Guo L, Huang B, Guo H, Liu G, Zhuang T, Liu W, Luo T, Wu Y, Peng G, Li D, Chen C. Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy. Radiat Oncol 2021;16:8. [PMID: 33436018 DOI: 10.1186/s13014-020-01699-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Xia X, Liu Z, Cai B, Di X, Sun X, Ge X. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma. Cancer Radiother 2021;25:39-44. [PMID: 33419607 DOI: 10.1016/j.canrad.2020.06.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Xia X, Liu Z, Qin Q, Di X, Zhang Z, Sun X, Ge X. Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:604657. [PMID: 33489910 DOI: 10.3389/fonc.2020.604657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
129 Wang J, Ma X, Si H, Ma Z, Ma Y, Wang J, Cao B. Role of long non-coding RNA H19 in therapy resistance of digestive system cancers. Mol Med 2021;27:1. [PMID: 33402118 DOI: 10.1186/s10020-020-00255-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Anker CJ, Dragovic J, Herman JM, Bianchi NA, Goodman KA, Jones WE, Kennedy TJ, Kumar R, Lee P, Russo S, Sharma N, Small W, Suh WW, Tchelebi LT, Jabbour SK. Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. International Journal of Radiation Oncology*Biology*Physics 2021;109:186-200. [DOI: 10.1016/j.ijrobp.2020.08.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Yang X, Zhai Y, Bi N, Zhang T, Deng L, Wang W, Wang X, Chen D, Zhou Z, Wang L, Liang J. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. Chin J Cancer Res 2021;33:53-60. [PMID: 33707928 DOI: 10.21147/j.issn.1000-9604.2021.01.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Booka E, Tsubosa Y, Haneda R, Ishii K. Ability of Laparoscopic Gastric Mobilization to Prevent Pulmonary Complications After Open Thoracotomy or Thoracoscopic Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis. World J Surg 2020;44:980-9. [PMID: 31722075 DOI: 10.1007/s00268-019-05272-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
133 Mishra S, Ahmad F, Singh S, Singh RK, Das KJM, Kumar S. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. Cancer Rep (Hoboken) 2021;4:e1332. [PMID: 33369258 DOI: 10.1002/cnr2.1332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
135 Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed MM. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst 2021;113:665-79. [PMID: 33351071 DOI: 10.1093/jnci/djaa195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Baumann BC, Mitra N, Harton JG, Xiao Y, Wojcieszynski AP, Gabriel PE, Zhong H, Geng H, Doucette A, Wei J, O'Dwyer PJ, Bekelman JE, Metz JM. Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. JAMA Oncol 2020;6:237-46. [PMID: 31876914 DOI: 10.1001/jamaoncol.2019.4889] [Cited by in Crossref: 23] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
137 Wang Y, Wang F. Postoperative Radiotherapy for Thoracic Esophageal Carcinoma with Upfront R0 Esophagectomy. Cancer Manag Res 2020;12:13023-32. [PMID: 33376396 DOI: 10.2147/CMAR.S286074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Ye Z, Zhao H, Zhou W, Ye T, Geng C, Li X, Yuan L, Du M, Xu H, Wang Q. Lower Serum Matrix Metalloproteinase‑9 in Metastatic Patients with Esophageal Squamous Cell Carcinoma After Concurrent Radiotherapy Was Significant for Prognosis. Onco Targets Ther 2020;13:12857-66. [PMID: 33364781 DOI: 10.2147/OTT.S280791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Kageyama SI, Junyan D, Hojo H, Motegi A, Nakamura M, Tsuchihara K, Akimoto T. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. J Radiat Res. 2020;61:177-186. [PMID: 31976528 DOI: 10.1093/jrr/rrz088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
140 Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M, Nagata Y. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res 2021;62:142-8. [PMID: 33392619 DOI: 10.1093/jrr/rraa110] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
141 Wei X, Guo Z, Zhang W, Zhang T, Chen X, Dong J, Han D, Lei T, Du Q, Pang Q, Wang P. Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial. Prec Radiat Oncol 2020;4:113-9. [DOI: 10.1002/pro6.1105] [Reference Citation Analysis]
142 Dong D, Zhao D, Li S, Liu W, Du F, Xu X, Xiao S, Zheng B, Sun Y, Wang W. Nomogram to predict overall survival for patients with non-metastatic cervical esophageal cancer: a SEER-based population study. Ann Transl Med 2020;8:1588. [PMID: 33437787 DOI: 10.21037/atm-20-2505] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
143 Hu CY, Li YK, Li JB, Wang JZ, Shao Q, Wang W, Guo YL, Xu M, Li WW. A comparative study of the normal oesophageal wall thickness based on 3-dimensional, 4-dimensional, and cone beam computed tomography. Medicine (Baltimore) 2020;99:e22553. [PMID: 33157916 DOI: 10.1097/MD.0000000000022553] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Zhang W, Zhao J, Han W, Zhang H, Wang X, Li C, Chen J, Wang X, Zhao Y, Qiao X, Zhou Z, Han C, Zhu S, Shen W, Wang L, Ge X, Sun X, Zhang K, Hu M, Li L, Hao C, Li G, Xu Y, Wang Y, Lu N, Liu M, Qian S, Xiao Z, Wang P, Pang Q. Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). Ann Transl Med 2020;8:1140. [PMID: 33240989 DOI: 10.21037/atm-20-4672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Pang Q, Wei X, Zhang W, Zhang T, Chen X, Dong J, Wei H, Er P, Zhao J, Han D, Guo Z, Lei T, Du Q, Guan Y, Wang J, Zhao L, Wang J, Yuan Z, Song Y, Liu N, Wang P. Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital. Ann Transl Med 2020;8:1156. [PMID: 33241005 DOI: 10.21037/atm-20-4064] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Hu L, Kong Z, Meng Q, Wang J, Zhou M, Yu J, Jiang X. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma. Med Sci Monit 2020;26:e927221. [PMID: 33243967 DOI: 10.12659/MSM.927221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
147 Xie Y, Wang Q, Cao B, Lv J, Wang Y, Wu L, Dong M, Li T. Textural features based enhanced contrast CT images predicts prognosis to concurrent chemoradiotherapy in stage III esophageal squamous cell cancer. Cancer Biomark 2020;27:325-33. [PMID: 31903981 DOI: 10.3233/CBM-190586] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Baba S, Sugimura H, Murai J, Pommier Y, Furuta T. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer 2020;20:1123. [PMID: 33218331 DOI: 10.1186/s12885-020-07574-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
149 Hayashi T, Asahina Y, Nakanishi H, Terashima T, Okamoto K, Yamada S, Takatori H, Kitamura K, Mizukoshi E, Ninomiya I, Kaneko S. Evaluation of the efficacy and safety of salvage photodynamic therapy by talaporfin sodium for cervical esophageal cancers and lesions larger than 3 cm. Esophagus 2021;18:645-54. [PMID: 33201316 DOI: 10.1007/s10388-020-00799-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Shi M, Tang J, Cao Z. Nomograms for predicting survival in early-onset esophageal cancer. Expert Review of Gastroenterology & Hepatology 2021;15:437-46. [DOI: 10.1080/17474124.2021.1842194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Wong IYH, Lam KO, Zhang RQ, Chan WWL, Wong CLY, Chan FSY, Kwong DLW, Law SYK. Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study. Annals of Surgery 2020;272:779-85. [DOI: 10.1097/sla.0000000000004329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
152 Qin Q, Ge X, Wang X, Wang L, Li C, Chen J, Wang X, Zhao Y, Zhang W, Wang P, Pang Q, Zhang K, Li L, Hu M, Hao C, Li G, Xu Y, Qiao X, Zhou Z, Zhu S, Shen W, Wang Y, Lu N, Liu M, Qie S, Han C, Xiao Z, Sun X. Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study. Front Oncol 2020;10:580450. [PMID: 33123483 DOI: 10.3389/fonc.2020.580450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Ishiyama K, Fujita T, Fujiwara H, Kurita D, Oguma J, Katai H, Daiko H. Does staged surgical training for minimally invasive esophagectomy have an impact on short-term outcomes? Surg Endosc 2020. [PMID: 33128077 DOI: 10.1007/s00464-020-08125-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
154 Vanneste BGL, Van Limbergen EJ, Dubois L, Samarska IV, Wieten L, Aarts MJB, Marcelissen T, De Ruysscher D. Immunotherapy as sensitizer for local radiotherapy. Oncoimmunology 2020;9:1832760. [PMID: 33194319 DOI: 10.1080/2162402X.2020.1832760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
155 Yang Y, Ge H. Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma. Future Oncol 2020;16:2537-49. [PMID: 33108227 DOI: 10.2217/fon-2020-0222] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
156 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 2020;5:951-8. [PMID: 33083658 DOI: 10.1016/j.adro.2020.03.020] [Reference Citation Analysis]
158 Yao X, Chen H, Xu B, Lu J, Gu J, Chen F, Ju M, Sun X. The ATPase subunit of ATP6V1C1 inhibits autophagy and enhances radiotherapy resistance in esophageal squamous cell carcinoma. Gene 2021;768:145261. [PMID: 33183740 DOI: 10.1016/j.gene.2020.145261] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
159 Zhang-Velten ER, Eraj SA, Hein DM, Aguilera TA, Folkert MR, Sanford NN. Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016. Adv Radiat Oncol 2021;6:100580. [PMID: 33732955 DOI: 10.1016/j.adro.2020.09.020] [Reference Citation Analysis]
160 Zhao S, Qi W, Chen J. Role of a multidisciplinary team in administering radiotherapy for esophageal cancer. BMC Cancer 2020;20:974. [PMID: 33032547 DOI: 10.1186/s12885-020-07467-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Buckle GC, Mahapatra R, Mwachiro M, Akoko L, Mmbaga EJ, White RE, Bent S, Van Loon K. Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies. Int J Cancer 2021;148:1115-31. [PMID: 32930395 DOI: 10.1002/ijc.33299] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
162 Luo H, Jiang W, Ma L, Chen P, Fang M, Ding L, Hua Y, Du D, Jing Z, Xie R, Song Y, Wang J, Zhou R, Tian Z, Wu S. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial. JAMA Netw Open 2020;3:e2019440. [PMID: 33026449 DOI: 10.1001/jamanetworkopen.2020.19440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
163 Wang J, Yu J, Jiang Y, Pei D, Zhu H, Wang J. Hypofractionated Radiotherapy in Combination With Chemotherapy Improves Outcome of Patients With Esophageal Carcinoma Tracheoesophageal Groove Lymph Node Metastasis. Front Oncol 2020;10:1540. [PMID: 32984011 DOI: 10.3389/fonc.2020.01540] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
164 Zhao Z, Wen Y, Liao D, Miao J, Gui Y, Cai H, Chen Y, Wei M, Jia Q, Tian H, Sun M, Zhang Y, Feng G, Du X. Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial. Oncologist 2020;25:e1900-8. [PMID: 32864805 DOI: 10.1634/theoncologist.2020-0808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
165 Li J, Wen Y, Xiang Z, Du H, Geng L, Yang X, Zhang Y, Bai J, Dai T, Feng G, Liu L, Du X. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol 2021;154:201-6. [PMID: 32980382 DOI: 10.1016/j.radonc.2020.09.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
166 Rodrigues-pinto E, Ferreira-silva J, Sousa-pinto B, Medas R, Garrido I, Siersema PD, Pereira P, Macedo G. Self-expandable metal stents in esophageal cancer before preoperative neoadjuvant therapy: efficacy, safety, and long-term outcomes. Surg Endosc 2021;35:5130-9. [DOI: 10.1007/s00464-020-08002-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
167 Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, Deng L, Wang W, Liu W, Liang J, Zhang T, Bi N, Wang J, Zhai Y, Feng Q, Lv J, Li L, Xiao Z. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer 2020;20:901. [PMID: 32962674 DOI: 10.1186/s12885-020-07387-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
168 Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg 2020;272:311-8. [PMID: 32675544 DOI: 10.1097/SLA.0000000000003228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
169 Chang X, Deng L, Ni W, Li C, Han W, Gao LR, Wang S, Zhou Z, Chen D, Feng Q, Liang J, Bi N, Lv J, Gao S, Mao Y, Xue Q, Xiao Z. Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer 2020;20:877. [PMID: 32928136 DOI: 10.1186/s12885-020-07315-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Lu HW, Chen CC, Chen HH, Yeh HL. The clinical outcomes of elderly esophageal cancer patients who received definitive chemoradiotherapy. J Chin Med Assoc 2020;83:906-10. [PMID: 32889988 DOI: 10.1097/JCMA.0000000000000419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Wang C, Zhao K, Hu S, Huang Y, Ma L, Li M, Song Y. The PET-Derived Tumor-to-Liver Standard Uptake Ratio (SUV TLR ) Is Superior to Tumor SUVmax in Predicting Tumor Response and Survival After Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer. Front Oncol 2020;10:1630. [PMID: 33014819 DOI: 10.3389/fonc.2020.01630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
172 Zhao J, Lei T, Zhang T, Chen X, Dong J, Guan Y, Wang J, Wei H, Er P, Han D, Wei X, Guo Z, Du Q, Wang J, Liu N, Song Y, Yuan Z, Zhao L, Zhang W, Pang Q, Wang P. The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Ann Transl Med 2020;8:1160. [PMID: 33241009 DOI: 10.21037/atm-20-4366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
173 Seyedin SN, Gannon MK, Plichta KA, Abushahin L, Berg DJ, Arshava EV, Parekh KR, Keech JC, Caster JM, Welsh JW, Allen BG. Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. Front Oncol 2020;10:1311. [PMID: 32850412 DOI: 10.3389/fonc.2020.01311] [Reference Citation Analysis]
174 Lyu J, Yisikandaer A, Li T, Zhang X, Wang X, Tian Z, Chen L, Lu B, Chen H, Yang J, Wang Q, Zhang J, Ma Y, Liu R, Liu R, Hage A, Lang J. Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China. Cancer Med 2020;9:7460-8. [PMID: 32841543 DOI: 10.1002/cam4.3409] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
175 Li KJ, Gu WY, Xia XF, Zhang P, Zou CL, Fei ZH. High Mean Corpuscular Volume as a Predictor of Poor Overall Survival in Patients with Esophageal Cancer Receiving Concurrent Chemoradiotherapy. Cancer Manag Res 2020;12:7467-74. [PMID: 32903963 DOI: 10.2147/CMAR.S230274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Bruna M, Mingol F, Vaqué FJ; Sección de Cirugía Esofagogástrica de la Asociación Española de Cirujanos. Results of a National Survey about Therapeutic Management in Esophageal Cancer. Cir Esp (Engl Ed) 2021;99:329-38. [PMID: 32788047 DOI: 10.1016/j.ciresp.2020.06.021] [Reference Citation Analysis]
177 Moon SH, Suh YG. The Role of Modern Radiotherapy Technology in the Treatment of Esophageal Cancer. Korean J Thorac Cardiovasc Surg 2020;53:184-90. [PMID: 32793450 DOI: 10.5090/kjtcs.2020.53.4.184] [Reference Citation Analysis]
178 Sun X, Wang L, Wang Y, Kang J, Jiang W, Men Y, Hui Z. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis. Front Oncol 2020;10:1222. [PMID: 32850362 DOI: 10.3389/fonc.2020.01222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
179 Al-Kaabi A, Schoon EJ, Deprez PH, Seewald S, Groth S, Giovannini M, Braden B, Berr F, Lemmers A, Hoare J, Bhandari P, van der Post RS, Verhoeven RHA, Siersema PD. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience. Gastrointest Endosc 2021;93:888-898.e1. [PMID: 32763242 DOI: 10.1016/j.gie.2020.07.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
180 DeCesaris CM, Berger M, Choi JI, Carr SR, Burrows WM, Regine WF, Simone CB 2nd, Molitoris JK. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointest Oncol 2020;11:663-73. [PMID: 32953150 DOI: 10.21037/jgo-20-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
181 de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, Bogers JHA, Braam PM, Muijs CKT, de Jong MA, Kasperts N, Rozema T, Jeene PM, Blom GJ, van Dieren JM, Hulshof MCCM, van Laarhoven HWM, Grabsch HI, Lemmens VEPP, Tjan-Heijnen VCG, Nieuwenhuijzen GAP. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol 2020;59:895-903. [PMID: 32319845 DOI: 10.1080/0284186X.2020.1753889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
182 Das A, Surendran S, Mathew M, Irodi A, Singh A, Joel A, Yacob M, Isiah R, Samarasam I, John S, Pavamani S, Sasidharan BK. Patterns of Recurrence in Locally Advanced Resectable Oesophageal Carcinoma: Retrospective Review from a Tertiary Cancer Centre in South India. J Gastrointest Cancer 2021;52:711-8. [PMID: 32720121 DOI: 10.1007/s12029-020-00464-2] [Reference Citation Analysis]
183 Ono T. Review of clinical results of charged-particle therapy for esophageal cancer. Esophagus 2021;18:33-40. [PMID: 32654019 DOI: 10.1007/s10388-020-00759-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 2020;9:5881-8. [PMID: 32627960 DOI: 10.1002/cam4.3273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
185 von Döbeln GA, Wagenius G, Holtved E, Jacobsen AB, Nilsson M, Yu J, Baeksgaard L. Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction. Cancer Treat Res Commun 2020;24:100187. [PMID: 32619832 DOI: 10.1016/j.ctarc.2020.100187] [Reference Citation Analysis]
186 Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. Front Oncol 2020;10:997. [PMID: 32656085 DOI: 10.3389/fonc.2020.00997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
187 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
188 Wang C, Zhao K, Hu S, Huang Y, Ma L, Song Y, Li M. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR. BMC Cancer 2020;20:544. [PMID: 32522277 DOI: 10.1186/s12885-020-07040-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
189 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thorac Cancer 2020;11:2170-7. [PMID: 32510875 DOI: 10.1111/1759-7714.13524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
190 Decesaris CM, Mccarroll R, Mishra MV, Glass E, Greenwald BD, Carr S, Burrows W, Mehra R, Regine WF, Simone CB, Choi JI, Molitoris JK. Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology 2020;15:1054-64. [DOI: 10.1016/j.jtho.2020.01.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
191 Sakai M, Sohda M, Saito H, Ubukata Y, Nakazawa N, Kuriyama K, Hara K, Sano A, Ogata K, Yokobori T, Shirabe K, Saeki H. Impact of combined assessment of systemic inflammation and presarcopenia on survival for surgically resected esophageal cancer. Am J Surg 2021;221:149-54. [PMID: 32594999 DOI: 10.1016/j.amjsurg.2020.05.029] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
192 Wang X, Wang P, Zhao Z, Mao Q, Yu J, Li M. A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Ther Adv Med Oncol 2020;12:1758835920926822. [PMID: 32518598 DOI: 10.1177/1758835920926822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
193 Rahimy E, Koong A, Toesca D, White MN, Panjwani N, Fisher G, Chang D, Pollom E. Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Adv Radiat Oncol 2020;5:1188-96. [PMID: 33305080 DOI: 10.1016/j.adro.2020.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
194 Kissel M, Chirat E, Annede P, Burtin P, Fumagalli I, Bronsart E, Mignot F, Schernberg A, Dumas I, Haie-Meder C, Chargari C. Esophageal brachytherapy: Institut Gustave Roussy's experience. Brachytherapy 2020;19:499-509. [PMID: 32444283 DOI: 10.1016/j.brachy.2020.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Inoue T, Ishihara R. Photodynamic Therapy for Esophageal Cancer. Clin Endosc 2021;54:494-8. [PMID: 32422695 DOI: 10.5946/ce.2020.073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
196 Xiao L, Czito BG, Pang Q, Hui Z, Jing S, Shan B, Wang J. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. J Cancer 2020;11:4605-13. [PMID: 32489478 DOI: 10.7150/jca.44447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
197 Ishida N, Osawa S, Miyazu T, Kaneko M, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Sugimoto K. Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience. J Clin Med 2020;9:E1509. [PMID: 32429571 DOI: 10.3390/jcm9051509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
198 Zhang AD, Su XH, Shi GF, Han C, Wang L, Liu H, Zhang J, Zhang RH. Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Arch Med Res 2020;51:419-28. [PMID: 32418649 DOI: 10.1016/j.arcmed.2020.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
199 Zhao Z, Zhang Y, Wang X, Wang P, Geng X, Zhu L, Li M. The Prognostic Significance of Metastatic Nodal Size in Non-surgical Patients With Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:523. [PMID: 32373526 DOI: 10.3389/fonc.2020.00523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
200 Watanabe A, Taniguchi M, Kimura Y, Kikkawa T, Hosokawa M. Larynx-preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery for cervical esophageal cancer invading pharynx. Diseases of the Esophagus 2020;33:doaa020. [DOI: 10.1093/dote/doaa020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
201 Er P, Qian D, Zhang W, Zhang B, Wei H, Zhang T, Chen X, Wang Y, Zhao J, Wang Q, Pang Q, Wang P. The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy. Aging (Albany NY) 2020;12:6586-99. [PMID: 32330901 DOI: 10.18632/aging.102993] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
202 Liu Q, Xia Y, Chen Y, Zhang J, Deng J, Zhao K. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 2020;15:75. [PMID: 32268925 DOI: 10.1186/s13014-020-01518-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
203 Luo H, Wei S, Wang X, Liu R, Zhang Q, Yang Z, Li Z, Wei X, Qi Y, Xu L. Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects. J Cancer 2020;11:3020-6. [PMID: 32226517 DOI: 10.7150/jca.41012] [Reference Citation Analysis]
204 Hu B, Jia F, Zhou H, Zhou T, Zhao Q, Chen Y, Li B, Huang W. Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma. J Cancer 2020;11:3693-700. [PMID: 32284766 DOI: 10.7150/jca.39033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
205 Chen L, Bi S, Wei Q, Zhao Z, Wang C, Xie S. Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma. J Cell Mol Med 2020;24:5387-401. [PMID: 32237037 DOI: 10.1111/jcmm.15195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 Kawamoto T, Shikama N, Mine S, Tsurumaru M, Sasai K. Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients. Esophagus 2020;17:425-32. [PMID: 32170545 DOI: 10.1007/s10388-020-00731-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
207 Cai G, Li C, Yu J, Meng X. Heart Dosimetric Parameters Were Associated With Cardiac Events and Overall Survival for Patients With Locally Advanced Esophageal Cancer Receiving Definitive Radiotherapy. Front Oncol 2020;10:153. [PMID: 32226770 DOI: 10.3389/fonc.2020.00153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
208 Fan XW, Wang HB, Mao JF, Li L, Wu KL. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study. Cancer Med 2020;9:2812-9. [PMID: 32100452 DOI: 10.1002/cam4.2933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
209 Vošmik M, Hodek M, Buka D, Sýkorová P, Grepl J, Paluska P, Paulíková S, Sirák I. Cardiotoxicity of radiation therapy in esophageal cancer. Rep Pract Oncol Radiother 2020;25:318-22. [PMID: 32194352 DOI: 10.1016/j.rpor.2020.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
210 Huang C, Huang D, Zhu Y, Xie G, Wang H, Shi J, Jia B, Yuan Y, Zhang W. Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined with Radiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma. Transl Oncol 2020;13:100736. [PMID: 32092670 DOI: 10.1016/j.tranon.2019.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
211 Ni W, Yang J, Deng W, Xiao Z, Zhou Z, Zhang H, Chen D, Feng Q, Liang J, Lv J, Wang X, Wang X, Zhang T, Bi N, Deng L, Wang W. Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. BMC Cancer 2020;20:144. [PMID: 32087687 DOI: 10.1186/s12885-020-6622-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
212 Dai KY, Yu YC, Leu YS, Chi CW, Chan ML, Tsai CH, Lin HC, Huang WC, Chen YJ. Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer. J Clin Med 2020;9:E387. [PMID: 32024132 DOI: 10.3390/jcm9020387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
213 Cheng N, Liu Y, Zhao G, Xu Y, Zhang T, Chen Y, Yan G, Hu Y, Yao S, Wang Z, Wang C, Chen Z, Hu Z, Liu D, Chen T. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys 2020;106:340-8. [PMID: 31655197 DOI: 10.1016/j.ijrobp.2019.10.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Qiu X, Li J, Zhou H, Zhang M, Jiang C, Shen Z, Zhu X, Li A, Che Y, Wu T, Wang Z. Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma. Medicine (Baltimore) 2020;99:e18732. [PMID: 31977864 DOI: 10.1097/MD.0000000000018732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Tan L, Xiao Z, Zhang H, Chen D, Feng Q, Zhou Z, Lv J, Liang J, Yin W. Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma. Cancer Radiother 2020;24:21-7. [PMID: 32001131 DOI: 10.1016/j.canrad.2019.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
216 Kirli Bolukbas M, Karaca S. Effect of lung volume on helical radiotherapy in esophageal cancer: are there predictive factors to achieve acceptable lung doses? Strahlenther Onkol 2020;196:805-12. [PMID: 31980833 DOI: 10.1007/s00066-020-01581-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Sato D, Motegi A, Kadota T, Kojima T, Bando H, Shinmura K, Hori K, Yoda Y, Oono Y, Zenda S, Ikematsu H, Akimoto T, Yano T. Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence. Esophagus 2020;17:305-11. [PMID: 31965362 DOI: 10.1007/s10388-020-00715-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
218 Yu S, Huang H, Wang S, Xu H, Xue Y, Huang Y, He J, Xu X, Wu Z, Wu J, Zhang Y, Huang Q, Chang Z, Li E, Xu L. CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2019;12:3301-10. [PMID: 31934173] [Reference Citation Analysis]
219 de Vos-Geelen J, Geurts SM, van Putten M, Valkenburg-van Iersel LB, Grabsch HI, Haj Mohammad N, Hoebers FJ, Hoge CV, Jeene PM, de Jong EJ, van Laarhoven HW, Rozema T, Slingerland M, Tjan-Heijnen VC, Nieuwenhuijzen GA, Lemmens VE. Trends in treatment and overall survival among patients with proximal esophageal cancer. World J Gastroenterol 2019; 25(47): 6835-6846 [PMID: 31885424 DOI: 10.3748/wjg.v25.i47.6835] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
220 Dai H, Shao YW, Tong X, Wu X, Pang J, Feng A, Yang Z. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma. Cancer Med 2020;9:1628-37. [PMID: 31851786 DOI: 10.1002/cam4.2761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
221 Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. [PMID: 31848929 DOI: 10.1007/s13402-019-00488-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
222 Sugawara K, Yagi K, Okumura Y, Nishida M, Aikou S, Yamashita H, Seto Y. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma. Int J Clin Oncol. 2020;25:552-560. [PMID: 31828451 DOI: 10.1007/s10147-019-01590-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
223 Yoshii T, Hara H, Asayama M, Kumekawa Y, Miyazawa S, Takahashi N, Matsushima T, Shimizu S, Saito Y. Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. Mol Clin Oncol 2020;12:23-30. [PMID: 31814973 DOI: 10.3892/mco.2019.1945] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
224 Sherry AD, Newman NB, Anderson JL, Osmundson EC. Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma. J Surg Oncol 2019;121:303-12. [DOI: 10.1002/jso.25793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
225 Zhang N, Gu M, Wang J, Wu S. Comparison of nodal irradiation dose using radiotherapy for patients with thoracic esophageal cancer. Oncol Lett 2020;19:1042-50. [PMID: 31897217 DOI: 10.3892/ol.2019.11178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
226 Sugawara K, Mori K, Yagi K, Aikou S, Uemura Y, Yamashita H, Seto Y. Association of preoperative inflammation-based prognostic score with survival in patients undergoing salvage esophagectomy. Dis Esophagus 2019;32:doy066. [PMID: 30535140 DOI: 10.1093/dote/doy066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
227 Wang C, Zhao K, Huang Y, Ma L, Song Y, Li M. Baseline FDG Uptake And Peripheral Lymphocyte-Monocyte Ratio For Predicting Chemoradiotherapy Response In Patients With Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2019;11:9085-93. [PMID: 31749632 DOI: 10.2147/CMAR.S227342] [Reference Citation Analysis]
228 Li X, Xing L, Zhang Y, Xie P, Zhu W, Meng X, Wang Y, Kong L, Zhao H, Yu J. Phase II Trial of Epigallocatechin-3-Gallate in Acute Radiation-Induced Esophagitis for Esophagus Cancer. J Med Food 2020;23:43-9. [PMID: 31747326 DOI: 10.1089/jmf.2019.4445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
229 Anderluh F, Toplak M, Velenik V, Oblak I, Ermenc AS, Peressutti AJ, But-Hadzic J, Vidmar MS. Definitive radiochemotherapy in esophageal cancer - a single institution experience. Radiol Oncol 2019;53:480-7. [PMID: 31747382 DOI: 10.2478/raon-2019-0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Xu X, Wang Z, Jiang S, Shang Y, Wu Y. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy. Radiat Oncol 2019;14:191. [PMID: 31684983 DOI: 10.1186/s13014-019-1402-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
231 Garant A, Whitaker TJ, Spears GM, Routman DM, Harmsen WS, Wilhite TJ, Ashman JB, Sio TT, Rule WG, Neben Wittich MA, Martenson JA, Tryggestad EJ, Yoon HH, Blackmon S, Merrell KW, Haddock MG, Hallemeier CL. A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer. Practical Radiation Oncology 2019;9:410-7. [DOI: 10.1016/j.prro.2019.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
232 Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S, Goody R, Hingorani M, Prince S, Bird T, Dorey N, Macgregor U, Al-Chamali H, Hurt C, Mukherjee S. Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clin Oncol (R Coll Radiol) 2020;32:121-30. [PMID: 31662220 DOI: 10.1016/j.clon.2019.09.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
233 Levinsky NC, Wima K, Morris MC, Ahmad SA, Shah SA, Starnes SL, Van Haren RM; Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Group. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2020;159:2555-66. [PMID: 31767364 DOI: 10.1016/j.jtcvs.2019.09.169] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
234 Luo HS, Huang HC, Lin LX. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis. Radiat Oncol 2019;14:178. [PMID: 31623639 DOI: 10.1186/s13014-019-1386-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
235 Kinsella T, Safran H, Wiersma S, DiPetrillo T, Schumacher A, Rosati K, Vatkevich J, Anderson LW, Hill KD, Kunos C, Collins JM. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation. Clin Cancer Res 2019;25:6035-43. [PMID: 31337643 DOI: 10.1158/1078-0432.CCR-19-0862] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
236 Guan H, Yu Y, Ge H, Zhu S, Huang W, Li B. Implication of clinical target delineation for T1b/T2 thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases. Future Oncol 2019;15:3345-55. [PMID: 31578872 DOI: 10.2217/fon-2019-0266] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
237 Wang X, Liu X, Li B. ASO Author Reflections: Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2019;26:741-2. [PMID: 31549314 DOI: 10.1245/s10434-019-07832-8] [Reference Citation Analysis]
238 Xu H, Wu S, Luo H, Chen C, Lin L, Huang H, Xue R. Prognostic value of tumor length and diameter for esophageal squamous cell cancer patients treated with definitive (chemo)radiotherapy: Potential indicators for nonsurgical T staging. Cancer Med 2019;8:6326-34. [PMID: 31486278 DOI: 10.1002/cam4.2532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
239 Zhao Z, Zhang Y, Wang P, Wang X, Li M. The impact of the nodal status on the overall survival of non-surgical patients with esophageal squamous cell carcinoma. Radiat Oncol 2019;14:161. [PMID: 31481064 DOI: 10.1186/s13014-019-1365-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
240 Kawamoto T, Shikama N, Oshima M, Kosugi Y, Tsurumaru M, Sasai K. Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. J Geriatr Oncol 2020;11:675-9. [PMID: 31471169 DOI: 10.1016/j.jgo.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
241 Suzuki G, Yamazaki H, Aibe N, Masui K, Kimoto T, Shimizu D, Nishimura T, Nakashima A, Machida K, Kawabata K, Ota Y, Fujiwara H, Ishikawa T, Yamada K. Definitive Radiotherapy for Older Patients Aged ≥75 Years With Localized Esophageal Cancer. In Vivo 2019;33:925-32. [PMID: 31028218 DOI: 10.21873/invivo.11560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
242 Wang Y, Wang L, Fang M, Li J, Song T, Zhan W, Xu H. Prognostic Value of the Geriatric Nutritional Risk Index in Patients Exceeding 70 Years Old with Esophageal Squamous Cell Carcinoma. Nutr Cancer 2020;72:620-6. [PMID: 31390885 DOI: 10.1080/01635581.2019.1650189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
243 Di Corpo M, Schlottmann F, Strassle PD, Nurczyk K, Patti MG. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes. Journal of Laparoendoscopic & Advanced Surgical Techniques 2019;29:989-94. [DOI: 10.1089/lap.2019.0350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
244 Zhu H, Pan W, Chen Y, Chen H, Zuo Y, Sun X. What Is the Optimal Radiotherapy Target Size for Non-Operable Esophageal Cancer? A Meta-Analysis. Oncol Res Treat 2019;42:470-9. [PMID: 31344698 DOI: 10.1159/000501594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
245 Wang L, Li C, Meng X, Li C, Sun X, Shang D, Pang L, Li Y, Lu J, Yu J. Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location. Front Oncol 2019;9:674. [PMID: 31404144 DOI: 10.3389/fonc.2019.00674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
246 Wang Q, Cao B, Chen J, Li C, Tan L, Zhang W, Lv J, Li X, Xiao M, Lin Y, Lang J, Li T, Xiao Z. Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma. Sci Rep 2019;9:10497. [PMID: 31324827 DOI: 10.1038/s41598-019-46899-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
247 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel) 2019;11:E993. [PMID: 31315281 DOI: 10.3390/cancers11070993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
248 Wang J, Yu J, Wang J, Ni X, Sun Z, Sun W, Sun S, Lu Y. Thalidomide combined with chemo-radiotherapy for treating esophageal cancer: A randomized controlled study. Oncol Lett 2019;18:804-13. [PMID: 31289557 DOI: 10.3892/ol.2019.10354] [Reference Citation Analysis]
249 Hartfiel S, Häfner M, Perez RL, Rühle A, Trinh T, Debus J, Huber PE, Nicolay NH. Differential response of esophageal cancer cells to particle irradiation. Radiat Oncol 2019;14:119. [PMID: 31286978 DOI: 10.1186/s13014-019-1326-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
250 Liu S, Ren SN, Ding WX, Ge XL, Cao YD, Zhang S, Zhen FX, Sun XC. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy. Ann Transl Med 2019;7:331. [PMID: 31475201 DOI: 10.21037/atm.2019.06.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
251 Halpern AL, Mccarter MD. Palliative Management of Gastric and Esophageal Cancer. Surgical Clinics of North America 2019;99:555-69. [DOI: 10.1016/j.suc.2019.02.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
252 Minamide T, Yoda Y, Hori K, Shinmura K, Oono Y, Ikematsu H, Yano T. Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Surg Endosc 2020;34:899-906. [DOI: 10.1007/s00464-019-06846-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
253 Han D, Yuan Y, Chai J, Zhang G, Wang L, Ren A, Song P, Fu Z, Yu J. Subclinical Lesions of the Primary Clinical Target Volume Margin in Esophageal Squamous Cell Carcinoma and Association With FDG PET/CT. Front Oncol 2019;9:336. [PMID: 31114759 DOI: 10.3389/fonc.2019.00336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
254 Liu C, Bhangoo RS, Sio TT, Yu NY, Shan J, Chiang JS, Ding JX, Rule WG, Korte S, Lara P, Ding X, Bues M, Hu Y, DeWees T, Ashman JB, Liu W. Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small-spot intensity-modulated proton versus volumetric-modulated arc therapies. J Appl Clin Med Phys 2019;20:15-27. [PMID: 31112371 DOI: 10.1002/acm2.12623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
255 Du XX, Yu R, Wang ZF, Du DC, Liu QY, Wang RM, Kang SR, Yang H. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy. Bosn J Basic Med Sci 2019;19:186-94. [PMID: 30877837 DOI: 10.17305/bjbms.2019.3873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
256 Wang J, Yu JP, Ni XC, Sun ZQ, Sun W, Nie B, Sun SP, Wang JL. Pathological response and serum VEGF changes during chemoradiotherapy for esophageal carcinoma. Medicine (Baltimore) 2019;98:e15627. [PMID: 31096474 DOI: 10.1097/MD.0000000000015627] [Reference Citation Analysis]
257 Hasatani K, Tamamura H, Yamamoto K, Aoyagi H, Miyanaga T, Kaizaki Y, Sawada T. Efficacy of Endoscopic Evaluation of Acute Radiation Esophagitis during Chemoradiotherapy with Proton Beam Therapy Boost for Esophageal Cancer. Digestion 2020;101:366-74. [PMID: 31067539 DOI: 10.1159/000500039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
258 Chen NB, Qiu B, Zhang J, Qiang MY, Zhu YJ, Wang B, Guo JY, Cai LZ, Huang SM, Liu MZ, Li Q, Hu YH, Li QW, Liu H. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities. Cancer Res Treat 2020;52:31-40. [PMID: 31048664 DOI: 10.4143/crt.2018.624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
259 Zhou XL, Zhu WG, Zhu ZJ, Wang WW, Deng X, Tao WJ, Ji FZ, Tong YS. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy. Oncologist 2019;24:e677-86. [PMID: 31040254 DOI: 10.1634/theoncologist.2018-0723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
260 Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, Wang J, Yuan Z, Wang P, Lin SH. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 2019;17:17-23. [PMID: 31080898 DOI: 10.1016/j.ctro.2019.04.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
261 Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Chen J. Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. Cancer Manag Res. 2019;11:3361-3369. [PMID: 31114372 DOI: 10.2147/cmar.s198524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
262 Lv J, Gan H, Zhang W, Pan L, Wang R, Qin Y. Relative tumor volume is a better independent prognostic factor in esophageal squamous cell carcinoma: Results of a retrospective study. Medicine (Baltimore) 2019;98:e14963. [PMID: 30946321 DOI: 10.1097/MD.0000000000014963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Hofheinz F, Li Y, Steffen IG, Lin Q, Lili C, Hua W, van den Hoff J, Zschaeck S. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:1485-94. [PMID: 30949816 DOI: 10.1007/s00259-019-04307-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
264 Deng W, Xu C, Liu A, van Rossum PS, Deng W, Liao Z, Koong AC, Mohan R, Lin SH. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiotherapy and Oncology 2019;133:9-15. [DOI: 10.1016/j.radonc.2018.12.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
265 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Li SH. The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis. Cancers (Basel) 2019;11:E451. [PMID: 30934987 DOI: 10.3390/cancers11040451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
266 Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, Tang H, Fan M, Li L, Lin Q, Xia Y, Li Y, Li J, Jia H, Lu S, Zhang Z, Zhao K. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol 2019;37:1695-703. [PMID: 30920880 DOI: 10.1200/JCO.18.02122] [Cited by in Crossref: 30] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
267 Batra R, Malhotra GK, Singh S, Are C. Managing Squamous Cell Esophageal Cancer. Surg Clin North Am 2019;99:529-41. [PMID: 31047040 DOI: 10.1016/j.suc.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
268 Moaven O, Wang TN. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. Surg Clin North Am 2019;99:479-99. [PMID: 31047037 DOI: 10.1016/j.suc.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
269 Yamashita K, Mine S, Toihata T, Fukudome I, Okamura A, Yuda M, Hayami M, Imamura Y, Watanabe M. The usefulness of three-dimensional video-assisted thoracoscopic esophagectomy in esophageal cancer patients. Esophagus 2019;16:272-7. [PMID: 30888533 DOI: 10.1007/s10388-019-00661-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
270 Pan G, Pan H, Zhang Y, Shuai H. Effects of lymph node metastasis of thoracic esophageal squamous cell carcinoma on design of radiotherapy target volume. Pak J Med Sci 2019;35:177-82. [PMID: 30881419 DOI: 10.12669/pjms.35.1.431] [Reference Citation Analysis]
271 Li C, Ni W, Wang X, Zhou Z, Deng W, Chang X, Chen D, Feng Q, Liang J, Wang X, Deng L, Wang W, Bi N, Zhang T, Xiao Z. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol 2019;14:48. [PMID: 30876442 DOI: 10.1186/s13014-019-1249-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
272 Fabian D, Ayan A, DiCostanzo D, Barney CL, Aljabban J, Diaz DA, Miller ED, Wuthrick E, Williams TM, Bazan JG. Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer. Front Oncol 2019;9:147. [PMID: 30931257 DOI: 10.3389/fonc.2019.00147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
273 Li Y, Dong H, Tan S, Qian Y, Jin W. Effects of thoracic epidural anesthesia/analgesia on the stress response, pain relief, hospital stay, and treatment costs of patients with esophageal carcinoma undergoing thoracic surgery: A single-center, randomized controlled trial. Medicine (Baltimore) 2019;98:e14362. [PMID: 30762735 DOI: 10.1097/MD.0000000000014362] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
274 Li W, Chen P, Zhang N, Song T, Wu S. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study. Oncologist 2019;24:461-e136. [PMID: 30850562 DOI: 10.1634/theoncologist.2019-0119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
275 Wu H, Minamide T, Yano T. Role of photodynamic therapy in the treatment of esophageal cancer. Dig Endosc 2019;31:508-16. [PMID: 30667112 DOI: 10.1111/den.13353] [Cited by in Crossref: 29] [Cited by in F6Publishing: 46] [Article Influence: 9.7] [Reference Citation Analysis]
276 Hamer PW, Hight SC, Ward IG, Harris DL, Woodham BL, Flint RS. Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience. ANZ J Surg 2019;89:367-71. [PMID: 30791194 DOI: 10.1111/ans.14981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
277 Wu J, Ni M, Zhu J, Wang K, Zhang D, Liu S. Clinical Evaluation of Javanica Oil Emulsion Injection Combined with the Radiotherapy in the Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis. J Altern Complement Med 2019;25:542-51. [PMID: 30785303 DOI: 10.1089/acm.2018.0096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
278 Ding WX, Liu S, Ma JX, Pu J, Wang HJ, Zhang S, Sun XC. Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells. Cancer Cell Int 2019;19:36. [PMID: 30820189 DOI: 10.1186/s12935-019-0752-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
279 Chen WK, Chen CA, Chi CW, Li LH, Lin CP, Shieh HR, Hsu ML, Ko CC, Hwang JJ, Chen YJ. Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy. J Clin Med 2019;8:E187. [PMID: 30764514 DOI: 10.3390/jcm8020187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
280 Jones CM, Spencer K, Hitchen C, Pelly T, Wood B, Hatfield P, Crellin A, Sebag-Montefiore D, Goody R, Crosby T, Radhakrishna G. Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis. Clin Oncol (R Coll Radiol) 2019;31:356-64. [PMID: 30737068 DOI: 10.1016/j.clon.2019.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
281 Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, Gubat JA, Chen Y. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther 2019;13:539-53. [PMID: 30787595 DOI: 10.2147/DDDT.S189514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
282 Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy. Biomed Res Int 2019;2019:1263050. [PMID: 30834254 DOI: 10.1155/2019/1263050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
283 He J, Wei W, Yang Q, Wang Y. Phillygenin Exerts In Vitro and In Vivo Antitumor Effects in Drug-Resistant Human Esophageal Cancer Cells by Inducing Mitochondrial-Mediated Apoptosis, ROS Generation, and Inhibition of the Nuclear Factor kappa B NF-κB Signalling Pathway. Med Sci Monit 2019;25:739-45. [PMID: 30681987 DOI: 10.12659/MSM.913138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
284 Li Q, Zhu S, Li S, Deng W. Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation. Medicine (Baltimore) 2019;98:e14080. [PMID: 30653123 DOI: 10.1097/MD.0000000000014080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
285 Jimenez-Jimenez E, Mateos P, Ortiz I, Aymar N, Roncero R, Gimenez M, Pardo J, Sabater S. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy. Clin Transl Oncol 2019;21:1159-67. [PMID: 30661172 DOI: 10.1007/s12094-019-02038-6] [Reference Citation Analysis]
286 Fan XW, Wu JL, Wang HB, Liang F, Jiang GL, Wu KL. Three-dimensional conformal radiation therapy alone for esophageal squamous cell carcinoma: 10-year survival outcomes. Thorac Cancer 2019;10:519-25. [PMID: 30648821 DOI: 10.1111/1759-7714.12968] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
287 Blais E, Vendrely V, Sargos P, Créhange G, Huguet F, Maingon P, Simon JM, Bourdais R, Ozsahin M, Bourhis J, Clément-Colmou K, Belghith B, Proudhom Briois MA, Gilliot O, Dujols JP, Peyras A, Dupin C, Riet FG, Canova CH, Huertas A, Troussier I. [Chemoradiation for oesophageal cancer: A critical review of the literature]. Cancer Radiother 2019;23:62-72. [PMID: 30639379 DOI: 10.1016/j.canrad.2018.05.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
288 Kim TH, Lee IJ, Kim JH, Lee CG, Lee YC, Kim JW. High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study. Head Neck 2019;41:146-53. [PMID: 30548508 DOI: 10.1002/hed.25483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
289 Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Li A, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Li J, Chen J. Long Noncoding RNA FAM201A Mediates the Radiosensitivity of Esophageal Squamous Cell Cancer by Regulating ATM and mTOR Expression via miR-101. Front Genet 2018;9:611. [PMID: 30574162 DOI: 10.3389/fgene.2018.00611] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
290 Yamada K, Chigusa Y, Nomura M, Sakanaka K, Nakamura M, Yano S, Tsunoda S, Kondoh E, Mandai M. A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy. Case Rep Obstet Gynecol 2018;2018:1280582. [PMID: 30627462 DOI: 10.1155/2018/1280582] [Reference Citation Analysis]
291 Wong I, Law S. The management of mid & proximal oesophageal squamous cell carcinoma. Best Pract Res Clin Gastroenterol 2018;36-37:85-90. [PMID: 30551861 DOI: 10.1016/j.bpg.2018.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
292 Huang ZH, Ma XW, Zhang J, Li X, Lai NL, Zhang SX. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. BMC Cancer 2018;18:1170. [PMID: 30477458 DOI: 10.1186/s12885-018-5040-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
293 Jeene PM, van Laarhoven HWM, Hulshof MCCM. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Best Pract Res Clin Gastroenterol 2018;36-37:53-9. [PMID: 30551857 DOI: 10.1016/j.bpg.2018.11.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
294 Semenkovich TR, Samson PP, Hudson JL, Subramanian M, Meyers BF, Kozower BD, Kreisel D, Patterson GA, Robinson CG, Bradley JD, Puri V. Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes? Ann Thorac Surg 2019;107:903-11. [PMID: 30444988 DOI: 10.1016/j.athoracsur.2018.09.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
295 Faiz Z, Dijksterhuis WPM, Burgerhof JGM, Muijs CT, Mul VEM, Wijnhoven BPL, Smit JK, Plukker JTM. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy. Eur J Surg Oncol 2019;45:931-40. [PMID: 30447937 DOI: 10.1016/j.ejso.2018.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
296 Ren W, Sha H, Yan J, Wu P, Yang J, Li R, Zhang H, Yu L, Qian H, Liu B. Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. J Biomater Appl 2018;33:707-24. [PMID: 30388386 DOI: 10.1177/0885328218809019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
297 Li F, Ding N, Zhao Y, Yuan L, Mao Y. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis. Int J Surg. 2018;60:88-100. [PMID: 30389537 DOI: 10.1016/j.ijsu.2018.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
298 Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K. Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist 2019;24:163-e76. [PMID: 30361422 DOI: 10.1634/theoncologist.2018-0653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
299 Chiappa A, Andreoni B, Dionigi R, Spaggiari L, Foschi D, Polvani G, Orecchia R, Fazio N, Pravettoni G, Cossu ML, Galetta D, Venturino M, Ferrari C, Macone L, Crosta C, Bonanni B, Biffi R. A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. Crit Rev Oncol Hematol. 2018;132:161-168. [PMID: 30447922 DOI: 10.1016/j.critrevonc.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
300 Zhu H, Ge X, Lu Y, Zuo Y, Qin Q, Sun X, Yang M. Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. Oncol Lett 2019;17:594-602. [PMID: 30655806 DOI: 10.3892/ol.2018.9564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
301 Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Baba S, Sugimura H, Miyajima H, Furuta T. High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. Oncotarget 2018;9:34876-88. [PMID: 30405881 DOI: 10.18632/oncotarget.26172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
302 Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, Nagasaki K, Mochizuki T. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique. J Radiat Res 2018;59:291-7. [PMID: 29659940 DOI: 10.1093/jrr/rry029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
303 Zhang R, Jia M, Li P, Han J, Huang K, Li Q, Qiao Y, Xu T, Ruan P, Hu Q, Fan G, Song Q, Fu Z. Radiotherapy improves the survival of patients with metastatic esophageal squamous cell carcinoma: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
304 Nakajo K, Yoda Y, Hori K, Takashima K, Sinmura K, Oono Y, Ikematsu H, Yano T. Technical feasibility of endoscopic submucosal dissection for local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Gastrointestinal Endoscopy 2018;88:637-46. [DOI: 10.1016/j.gie.2018.06.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
305 Wang J, Qin J, Jing S, Liu Q, Cheng Y, Wang Y, Cao F. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis. Thorac Cancer 2018;9:1638-47. [PMID: 30277016 DOI: 10.1111/1759-7714.12874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
306 Lavin V, Mehta S, Sumra P, Wang X, Bhatt L, Jackson A, Sheikh H. Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability. Clinical Oncology 2018;30:650-7. [DOI: 10.1016/j.clon.2018.07.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
307 Wang D, Zhang W, Qian D, Guan Y, Chen X, Zhang H, Wang J, Pang Q. Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. Onco Targets Ther 2018;11:6333-8. [PMID: 30319273 DOI: 10.2147/OTT.S168275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
308 Wu CC, Li SH, Lu HI, Lo CM, Wang YM, Chou SY, Chen YH. Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. PeerJ 2018;6:e5655. [PMID: 30258731 DOI: 10.7717/peerj.5655] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
309 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
310 Soma D, Kawamura YI, Yamashita S, Wake H, Nohara K, Yamada K, Kokudo N. Sarcopenia, the depletion of muscle mass, an independent predictor of respiratory complications after oncological esophagectomy. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy092] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
311 Shi L, Lai Y, Chen S, Fu L, Lin Q. Dosimetric superiority of IMRT with jaw tracking technique for whole esophagus and T-shaped field radiotherapy in advanced esophageal cancer. PLoS One 2018;13:e0202628. [PMID: 30183753 DOI: 10.1371/journal.pone.0202628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
312 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 194] [Article Influence: 34.5] [Reference Citation Analysis]
313 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43. [PMID: 30171414 DOI: 10.1007/s10388-018-0642-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 171] [Article Influence: 29.3] [Reference Citation Analysis]
314 Li X, Hong X, Gao X, Gu X, Xiong W, Zhao J, Yu H, Cui M, Xie M, Bai Y, Sun S. Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3. Cancer Manag Res 2018;10:3149-58. [PMID: 30214307 DOI: 10.2147/CMAR.S166942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
315 Créhange G, Mabrut JY, Rouffiac M. [Surgery after upfront radiochemotherapy for locally advanced esophageal cancer: To do or not to do?]. Cancer Radiother 2018;22:540-5. [PMID: 30174168 DOI: 10.1016/j.canrad.2018.07.133] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Ogino I, Watanabe S, Hirasawa K, Misumi T, Hata M, Kunisaki C. The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control. In Vivo 2018;32:1269-74. [PMID: 30150456 DOI: 10.21873/invivo.11376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Fan CY, Su YF, Huang WY, Chao HL, Lin KT, Lin CS. Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer. Sci Rep 2018;8:12877. [PMID: 30150679 DOI: 10.1038/s41598-018-31302-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
318 Sun X, Martin RCG, Zheng Q, Farmer R, Pandit H, Li X, Jacob K, Suo J, Li Y. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma. Cell Oncol (Dordr) 2018;41:651-62. [PMID: 30116994 DOI: 10.1007/s13402-018-0399-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
319 Chen M, Shen M, Lin Y, Liu P, Liu X, Li X, Li A, Yang R, Ni W, Zhou X, Zhang L, Xu B, Lin J, Chen J, Tian Y. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Radiat Oncol 2018;13:150. [PMID: 30111361 DOI: 10.1186/s13014-018-1086-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
320 Zhang W, Luo Y, Wang X, Han G, Wang P, Yuan W, Dai SB. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. Cancer Manag Res 2018;10:2675-82. [PMID: 30147366 DOI: 10.2147/CMAR.S160909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
321 Sekii S, Ito Y, Harada K, Kitaguchi M, Takahashi K, Inaba K, Murakami N, Igaki H, Sasaki R, Itami J. Intrafraction esophageal motion in patients with clinical T1N0 esophageal cancer. Rep Pract Oncol Radiother 2018;23:398-401. [PMID: 30127681 DOI: 10.1016/j.rpor.2018.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
322 Sadrizadeh A, Bagheri R, Soltani E, Anvari K, Toussi MS, Moadikhah S. The Comparison of the Advantages of Neoadjuvant Chemoradiotherapy versus Postoperative Chemoradiotherapy: Outcomes in Esophageal Cancer Patients. J Gastrointest Cancer 2018;49:50-6. [PMID: 28025816 DOI: 10.1007/s12029-016-9899-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
323 Ishibashi N, Hata M, Maebayashi T, Aizawa T, Sakaguchi M, Okada M. Does protruding type 1 esophageal cancer really have a good response to radiation therapy?-a retrospective observational study. J Thorac Dis 2018;10:3512-8. [PMID: 30069348 DOI: 10.21037/jtd.2018.05.103] [Reference Citation Analysis]
324 Münch S, Pigorsch SU, Devečka M, Dapper H, Weichert W, Friess H, Braren R, Combs SE, Habermehl D. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol 2018;13:139. [PMID: 30068371 DOI: 10.1186/s13014-018-1085-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
325 Yoshimizu S, Yoshio T, Ishiyama A, Tsuchida T, Horiuchi Y, Omae M, Hirasawa T, Asari T, Chin K, Fujisaki J. Long-term outcomes of combined endoscopic resection and chemoradiotherapy for esophageal squamous cell carcinoma with submucosal invasion. Digestive and Liver Disease 2018;50:833-8. [DOI: 10.1016/j.dld.2018.01.138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
326 Badiyan SN, Roach MC, Chuong MD, Rice SR, Onyeuku NE, Remick J, Chilukuri S, Glass E, Mohindra P, Simone CB 2nd. Combining immunotherapy with radiation therapy in thoracic oncology. J Thorac Dis 2018;10:S2492-507. [PMID: 30206494 DOI: 10.21037/jtd.2018.05.73] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
327 Halder A, Biswas R, Ghosh A, Dastidar AG. Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study. J Contemp Brachytherapy 2018;10:225-31. [PMID: 30038642 DOI: 10.5114/jcb.2018.76843] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
328 Zhu W, Zhang Y, Kong L, Huang Y, Zheng J, Wang R, Li M, Yu J. 18F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. Onco Targets Ther 2018;11:4345-53. [PMID: 30100740 DOI: 10.2147/OTT.S160456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
329 Tamaki Y, Hieda Y, Nakajima M, Kitajima K, Yoshida R, Yoshizako T, Ue A, Tokudo M, Hirahara N, Moriyama I, Kato H, Inomata T. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil. J Cancer 2018;9:2765-72. [PMID: 30123343 DOI: 10.7150/jca.23456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
330 Effeney R, Shaw T, Burmeister BH, Burmeister E, Harvey J, Mai GT, Thomas J, Barbour AP, Smithers BM, Pryor DI. Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus. Clin Oncol (R Coll Radiol) 2018;30:642-9. [PMID: 30017206 DOI: 10.1016/j.clon.2018.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Valmasoni M, Pierobon ES, Zanchettin G, Briscolini D, Moletta L, Ruol A, Salvador R, Merigliano S. Cervical Esophageal Cancer Treatment Strategies: A Cohort Study Appraising the Debated Role of Surgery. Ann Surg Oncol. 2018;25:2747-2755. [PMID: 29987601 DOI: 10.1245/s10434-018-6648-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
332 Takeuchi M, Kawakubo H, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Suda K, Wada N, Takeuchi H, Kitagawa Y. Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer. J Gastrointest Surg 2018;22:1881-9. [PMID: 29980971 DOI: 10.1007/s11605-018-3857-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
333 Yu F, Shih H, Wu C, Chuang Y, Lee J, Li H, Fang P, Tsai D, Chou S, Wu I. Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding. Gastrointestinal Endoscopy 2018;88:21-31.e4. [DOI: 10.1016/j.gie.2017.11.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
334 Liu X, Li M, Duan Q, Qiao X, Yu J, Yue S. Prognostic role of neutrophil-to-lymphocyte ratio on esophageal cancer patients who received definitive chemoradiotherapy: Liu et al. Prec Radiat Oncol 2018;2:32-8. [DOI: 10.1002/pro6.42] [Reference Citation Analysis]
335 Chen H, Zhou L, Yang Y, Yang L, Chen L. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma. Med Sci Monit 2018;24:4183-91. [PMID: 29915168 DOI: 10.12659/MSM.910326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
336 Matsutani T, Nomura T, Hagiwara N, Matsuda A, Uchida E. Salvage Endoscopic Argon Plasma Coagulation After Chemoradiotherapy for Inoperable Esophageal Cancer. Surg Laparosc Endosc Percutan Tech 2017;27:384-90. [PMID: 28727635 DOI: 10.1097/SLE.0000000000000454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
337 Sugase T, Makino T, Yamasaki M, Tanaka K, Hashimoto T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mano M, Morii E, Mori M, Doki Y. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus 2018. [PMID: 29909488 DOI: 10.1007/s10388-018-0626-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Lee JW, Cho CJ, Kim DH, Ahn JY, Lee JH, Choi KD, Song HJ, Park SR, Lee HJ, Kim YH, Lee GH, Jung HY, Kim SB, Kim JH, Park SI. Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series. Clin Endosc 2018;51:470-7. [PMID: 29860747 DOI: 10.5946/ce.2018.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
339 Kawamoto T, Nihei K, Sasai K, Karasawa K. Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer. Esophagus 2018;15:256-62. [PMID: 30225742 DOI: 10.1007/s10388-018-0622-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
340 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
341 Liu C, Gao X. Determination of radiotherapy target volume for esophageal cancer. Prec Radiat Oncol 2018;2:52-60. [DOI: 10.1002/pro6.37] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
342 Kawakami T, Tsushima T, Omae K, Ogawa H, Shirasu H, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Machida N, Yokota T, Yamazaki K, Fukutomi A, Onozawa Y, Yasui H. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. BMC Cancer 2018;18:573. [PMID: 29776344 DOI: 10.1186/s12885-018-4486-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
343 Grimminger PP, der Horst S, Ruurda JP, Det M, Morel P, Hillegersberg R. Surgical robotics for esophageal cancer. Ann N Y Acad Sci 2018;1434:21-6. [DOI: 10.1111/nyas.13676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
344 Lu YF, Chung CS, Liu CY, Shueng PW, Wu LJ, Hsu CX, Kuo DY, Hou PY, Chou HL, Leong KI, How CH, Chou SF, Wang LY, Hsieh CH. Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not? Oncologist 2018;23:1426-35. [PMID: 29728468 DOI: 10.1634/theoncologist.2017-0646] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
345 Wang W, Xing D, Song Y, Liu F. Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2018;97:e0164. [PMID: 29561425 DOI: 10.1097/MD.0000000000010164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
346 Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 2018;94:345-53. [PMID: 29705797 DOI: 10.1159/000486720] [Reference Citation Analysis]
347 Tsou YK, Liang KH, Lin WR, Chang HK, Tseng CK, Yeh CT. GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:29151-60. [PMID: 28418863 DOI: 10.18632/oncotarget.16253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
348 Song GM, Tian X, Liu XL, Chen H, Zhou JG, Bian W, Chen WQ. Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis. Oncotarget 2017;8:37963-73. [PMID: 28415814 DOI: 10.18632/oncotarget.16302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
349 Zhang Y, Li Z, Zhang W, Chen W, Song Y. Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy. Onco Targets Ther 2018;11:2311-7. [PMID: 29731639 DOI: 10.2147/OTT.S161803] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
350 Li Y, Hofheinz F, Furth C, Lili C, Hua W, Ghadjar P, Zschaeck S. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1752-61. [PMID: 29679113 DOI: 10.1007/s00259-018-3996-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
351 Booka E, Takeuchi H, Suda K, Fukuda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Meta-analysis of the impact of postoperative complications on survival after oesophagectomy for cancer. BJS Open 2018;2:276-84. [PMID: 30263978 DOI: 10.1002/bjs5.64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
352 Yamashita K, Watanabe M, Mine S, Toihata T, Fukudome I, Okamura A, Yuda M, Hayami M, Ishizuka N, Imamura Y. Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis. Surg Endosc 2018;32:4443-50. [DOI: 10.1007/s00464-018-6187-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
353 Wu S, Wang L, Luo H, Xie C, Zhang X, Hu W, Zheng A, Li D, Zhang H, Xie C, Lian X, Du D, Chen M, Bian X, Tan B, Jiang H, Zhang H, Wang J, Jing Z, Xia B, Zhang N, Zhang P, Li W, Zhao F, Tian Z, Liu H, Huang K, Hu J, Xie R, Du L, Li G. Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer. European Journal of Cancer 2018;93:99-107. [DOI: 10.1016/j.ejca.2018.01.085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
354 Miyazaki T, Sohda M, Sakai M, Kumakura Y, Yoshida T, Kuriyama K, Yokobori T, Miyazaki M, Hirato J, Okumura T, Ishikawa H, Sakurai H, Kuwano H. Multimodality Therapy Including Proton Beam Therapy for AFP Producing Esophageal Cancer with Multiple Liver Metastases. Intern Med 2018;57:2333-9. [PMID: 29607947 DOI: 10.2169/internalmedicine.0270-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
355 Takeda K, Umezawa R, Takahashi N, Matsushita H, Kozumi M, Ishikawa Y, Yamamoto T, Takeda K, Jingu K. Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer. Esophagus 2018;15:190-7. [DOI: 10.1007/s10388-018-0612-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
356 Fan B, Fan P, Kong L, Sun X, Zhao S, Sun X, Fu Z, Zheng J, Ma L, Wang S, Hu M, Yu J. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget 2017;8:34498-506. [PMID: 28404900 DOI: 10.18632/oncotarget.15606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
357 Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P. ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer. Int J Mol Sci 2018;19:E868. [PMID: 29543757 DOI: 10.3390/ijms19030868] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
358 Kam TY, Kountouri M, Roth A, Frossard JL, Huber O, Mönig S, Zilli T. Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review. Crit Rev Oncol Hematol 2018;124:61-5. [PMID: 29548487 DOI: 10.1016/j.critrevonc.2018.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
359 Spatola C, Tocco A, Pagana A, Milazzotto R, Luigi R, Salamone V, Militello C, Migliore M, Foti PV, Cataldo AD, Acquaviva G, Privitera G. Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. Future Oncology 2018;14:47-51. [DOI: 10.2217/fon-2017-0342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
360 Watanabe A, Katada C, Komori S, Moriya H, Yamashita K, Harada H, Azuma M, Kondo Y, Kubota Y, Furue Y, Kawanishi N, Yamane S, Wada T, Yano T, Ishido K, Tanabe S, Hayakawa K, Koizumi W. Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study. Adv Radiat Oncol 2018;3:305-13. [PMID: 30197939 DOI: 10.1016/j.adro.2018.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
361 Chen Y, Zhu Z, Zhao W, Li L, Ye J, Wu C, Tang H, Lin Q, Li J, Xia Y, Li Y, Zhou J, Zhao K. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol. Radiat Oncol 2018;13:33. [PMID: 29482649 DOI: 10.1186/s13014-018-0979-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
362 Yap JC, Malhotra HK, Yang GY. Intensity modulated radiation therapy in the treatment of esophageal cancer. Thorac Cancer 2010;1:62-9. [PMID: 27755781 DOI: 10.1111/j.1759-7714.2010.00017.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
363 Zhao C, Lin L, Liu J, Liu R, Chen Y, Ge F, Jia R, Jin Y, Wang Y, Xu J. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma. Oncotarget 2016;7:57310-6. [PMID: 28087951 DOI: 10.18632/oncotarget.9809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
364 Xia Y, Li YH, Chen Y, Liu Q, Zhang JH, Deng JY, Ai TS, Zhu HT, Badakhshi H, Zhao KL. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Int J Clin Oncol 2018;23:458-65. [PMID: 29435872 DOI: 10.1007/s10147-018-1240-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
365 Shin HJ, Moon HS, Kang SH, Sung JK, Jeong HY, Kim SH, Lee BS, Kim JS, Yun GY. Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma: Is it a significant prognostic factor? Medicine (Baltimore) 2017;96:e9441. [PMID: 29390576 DOI: 10.1097/MD.0000000000009441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
366 Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, Moriya S, Tachibana H, Nakamura N, Kojima T, Akimoto T. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2018;13:23. [PMID: 29426342 DOI: 10.1186/s13014-018-0966-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
367 Tang Y, Li G, Wu S, Tang L, Zhang N, Liu J, Zhang S, Yao L. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. Oncol Lett 2018;15:4988-96. [PMID: 29552135 DOI: 10.3892/ol.2018.7984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
368 Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary Approach to the Management of Esophageal Malignancies. World J Surg 2017;41:1726-33. [PMID: 28361298 DOI: 10.1007/s00268-017-4009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
369 Singla S, Gabriel E, Alnaji R, Du W, Attwood K, Nava H, Hochwald SN, Kukar M. Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer. J Gastrointest Oncol. 2018;9:73-79. [PMID: 29564173 DOI: 10.21037/jgo.2017.09.11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
370 Park IH, Kim JY. Surveillance or resection after chemoradiation in esophageal cancer. Ann Transl Med 2018;6:82. [PMID: 29666805 DOI: 10.21037/atm.2017.12.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Chang H, Liaw CC, Chang HK. Therapy-Related Acute Myeloid Leukemia after Concurrent Chemoradiotherapy for Esophageal Cancer: Report of Two Cases. Tumori 2009;95:371-3. [DOI: 10.1177/030089160909500317] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
372 Go S, Lee WS, Kang MH, Song H, Kim MJ, Lee MJ, Kim H, Lee GW, Kang JH, Lee J, Kang KM, Jeon K, Cho JM, Jung WT, Ko GH. Response to Concurrent Chemoradiotherapy as a Prognostic Marker in Elderly Patients with Locally Advanced Esophageal Cancer. Tumori 2012;98:225-32. [DOI: 10.1177/030089161209800208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
373 Kundel Y, Levitt ML, Oberman B, Sadezki S, Tichler T, Symon Z, Catane R, Pfeffer R, Brenner B. Adjuvant Chemotherapy and Whole Abdominal Irradiation for Gastric Carcinoma. Tumori 2008;94:469-73. [DOI: 10.1177/030089160809400405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
374 Barney CL, Zamora P, Ewing A, Old M, Chakravarti A, Bhatt A. Synchronous Supraglottic and Esophageal Squamous Cell Carcinomas Treated with a Monoisocentric Hybrid Intensity-Modulated Radiation Technique. Front Oncol 2017;7:307. [PMID: 29359120 DOI: 10.3389/fonc.2017.00307] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
375 Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis. Radiat Oncol 2018;13:12. [PMID: 29357883 DOI: 10.1186/s13014-018-0958-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
376 Lancellotta V, Kovács G, Tagliaferri L, Perrucci E, Colloca G, Valentini V, Aristei C. Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer. Biomed Res Int 2018;2018:2178469. [PMID: 29581964 DOI: 10.1155/2018/2178469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
377 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
378 Chen F, Fang J, Wang H, Song T, Zhu W, Wu M, Wu Y. Effects of nutritional support on short-term clinical outcomes and immune response in unresectable locally advanced oesophageal squamous cell carcinoma. Eur J Cancer Care (Engl) 2018;27:e12818. [PMID: 29345017 DOI: 10.1111/ecc.12818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
379 Sakanaka K, Ishida Y, Fujii K, Itasaka S, Miyamoto S, Horimatsu T, Muto M, Mizowaki T. Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma. Radiat Oncol 2018;13:7. [PMID: 29347960 DOI: 10.1186/s13014-018-0957-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
380 Chen Y, Wang J. Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery. Radiother Oncol 2018;129:182. [PMID: 29331542 DOI: 10.1016/j.radonc.2017.12.019] [Reference Citation Analysis]
381 Hsieh HY, Hsu CP, Yeh HL, Chuang CY, Lin JF, Chang CF. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma. Kaohsiung J Med Sci 2018;34:281-9. [PMID: 29699635 DOI: 10.1016/j.kjms.2017.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
382 Huang CY, Lee CH, Tu CC, Wu CH, Huang MT, Wei PL, Chang YJ. Glucose-regulated protein 94 mediates progression and metastasis of esophageal squamous cell carcinoma via mitochondrial function and the NF-kB/COX-2/VEGF axis. Oncotarget 2018;9:9425-41. [PMID: 29507700 DOI: 10.18632/oncotarget.24114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
383 Zhang P, Xi M, Li QQ, Hu YH, Guo X, Zhao L, Liu H, Liu SL, Luo LL, Liu Q, Liu MZ. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Oncotarget 2016;7:44686-94. [PMID: 27183916 DOI: 10.18632/oncotarget.9301] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
384 Huang TC, Hsu CH. On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: additional evaluation by magnetic resonance imaging may help. Ann Transl Med 2017;5:487. [PMID: 29299449 DOI: 10.21037/atm.2017.09.38] [Reference Citation Analysis]
385 Adenis A, Piessen G, Azria D. Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence? Ann Transl Med 2017;5:503. [PMID: 29299464 DOI: 10.21037/atm.2017.10.27] [Reference Citation Analysis]
386 Kang J, Chang JY, Sun X, Men Y, Zeng H, Hui Z. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. J Cancer 2018;9:584-93. [PMID: 29483964 DOI: 10.7150/jca.20940] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
387 de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, Del Giglio A, Lazaretti NS, Álvares MN, Pedrini JL, Kussumoto C, de Matos Neto JN, Forones NM, Fernandes Júnior HJ, Borges G, Girotto G, da Silva IDCG, Maluf-filho F, Skare NG. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. European Journal of Cancer 2018;88:21-30. [DOI: 10.1016/j.ejca.2017.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
388 Ilson DH, van Hillegersberg R. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. Gastroenterology 2018;154:437-51. [DOI: 10.1053/j.gastro.2017.09.048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
389 Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res 2018;10:13-21. [PMID: 29343986 DOI: 10.2147/CMAR.S144687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
390 Li X, Zhao J, Liu M, Zhai F, Zhu Z, Yu F, Zhang M, Han L, Zhao Y, Wang H. Determination of radiotherapeutic target zones for thoracic esophageal squamous cell cancer with lower cervical lymph node metastasis according to CT-images. Oncotarget 2016;7:35865-73. [PMID: 27147581 DOI: 10.18632/oncotarget.9094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
391 Wen Y, Zhao Z, Miao J, Yang Q, Gui Y, Sun M, Tian H, Jia Q, Liao D, Yang C, Du X. S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial. Medicine (Baltimore) 2017;96:e8998. [PMID: 29245275 DOI: 10.1097/MD.0000000000008998] [Reference Citation Analysis]
392 Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol 2018;3:114-24. [PMID: 29248399 DOI: 10.1016/S2468-1253(17)30363-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
393 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
394 Nishiwaki N, Tsubosa Y, Niihara M. Salvage esophagectomy with pancreatectomy for local recurrence of thoracic esophageal cancer after definitive chemoradiotherapy: A case report. Int J Surg Case Rep 2018;42:85-9. [PMID: 29227857 DOI: 10.1016/j.ijscr.2017.11.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
395 Chen J, Guo H, Zhai T, Chang D, Chen Z, Huang R, Zhang W, Lin K, Guo L, Zhou M, Li D, Li D, Chen C. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget 2016;7:22711-9. [PMID: 26992206 DOI: 10.18632/oncotarget.8050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
396 Fazio N, Bertani E, Cella CA. Should cT2N0M0 be managed as a localized or locally advanced esophageal carcinoma? J Thorac Dis 2017;9:2829-34. [PMID: 29221250 DOI: 10.21037/jtd.2017.08.82] [Reference Citation Analysis]
397 Zhang P, Li Z, Wang D, Ma F, Zhang R, Liang W, Sun M, Fu Z, Sun X. 18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy. Oncol Lett 2018;15:1845-52. [PMID: 29434881 DOI: 10.3892/ol.2017.7528] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
398 Hayami M, Watanabe M, Ishizuka N, Mine S, Imamura Y, Okamura A, Kurogochi T, Yamashita K. Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. J Surg Oncol 2018;117:1251-9. [PMID: 29205358 DOI: 10.1002/jso.24941] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
399 Huang S, Zheng S, Gong T, Ma H, Ke Y, Zhao S, Wang W, Jia L, Zhang X. Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older. Oncotarget 2017;8:112094-102. [PMID: 29340114 DOI: 10.18632/oncotarget.22884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
400 Yap W, Chang Y, Hsieh C, Chao Y, Chen C, Shih M, Hung T. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018;45:689-98. [DOI: 10.1007/s00259-017-3901-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
401 Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol 2017;3:1520-8. [PMID: 28687830 DOI: 10.1001/jamaoncol.2017.1598] [Cited by in Crossref: 81] [Cited by in F6Publishing: 102] [Article Influence: 16.2] [Reference Citation Analysis]
402 Tobias JS, Hughes RAC. Treatment of Oesophageal Cancer. J R Soc Med 2002;95:55-55. [DOI: 10.1177/014107680209500126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
403 Chen Y, Guo L, Cheng X, Wang J, Zhang Y, Wang Y, Ke S, Shi W. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis. Radiother Oncol 2018;129:154-60. [PMID: 29122362 DOI: 10.1016/j.radonc.2017.10.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
404 Nomura M, Kato K, Ando N, Ohtsu A, Muro K, Igaki H, Abe T, Takeuchi H, Daiko H, Gotoh M, Kataoka K, Wakabayashi M, Kitagawa Y. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol 2017;47:480-6. [PMID: 28334858 DOI: 10.1093/jjco/hyx040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
405 Du D, Song T, Liang X, Fang M, Wu S. Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature. Dis Esophagus 2017;30:1-9. [PMID: 26918886 DOI: 10.1111/dote.12471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
406 Mikhail S, Wei L, Salem ME, Bekaii-Saab T. Outcomes of definitive chemoradiation in patients with esophageal cancer. Dis Esophagus 2017;30:1-7. [PMID: 27868290 DOI: 10.1111/dote.12506] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
407 Yang H, Feng C, Cai BN, Yang J, Liu HX, Ma L. Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma. Dis Esophagus 2017;30:1-8. [PMID: 27629865 DOI: 10.1111/dote.12497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.2] [Reference Citation Analysis]
408 Song T, Wan Q, Yu W, Li J, Lu S, Xie C, Wang H, Fang M. Pretreatment nutritional risk scores and performance status are prognostic factors in esophageal cancer patients treated with definitive chemoradiotherapy. Oncotarget 2017;8:98974-84. [PMID: 29228742 DOI: 10.18632/oncotarget.21940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
409 Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, Tada H, Yamamoto Y, Kataoka H, Kakushima N, Ishihara R, Isomoto H, Muto M. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 2017;8:22135-44. [PMID: 28212527 DOI: 10.18632/oncotarget.14029] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
410 Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers. Thorac Cancer 2018;9:59-65. [PMID: 29024498 DOI: 10.1111/1759-7714.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
411 Chen P, Fang M, Wan Q, Zhang X, Song T, Wu S. High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget 2017;8:99861-70. [PMID: 29245945 DOI: 10.18632/oncotarget.21734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
412 Zhu Y, Zhang W, Li Q, Li Q, Qiu B, Liu H, Liu M, Hu Y. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma. J Cancer 2017;8:3657-66. [PMID: 29151952 DOI: 10.7150/jca.20053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
413 Zhao L, Zhou Y, Mu Y, Chai G, Xiao F, Tan L, Lin SH, Shi M. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget 2017;8:21852-60. [PMID: 28423530 DOI: 10.18632/oncotarget.15665] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
414 Lee DY, Moon SH, Cho KH, Kim TH, Kim MS, Lee JY, Suh YG. Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer. Radiat Oncol J 2017;35:241-8. [PMID: 29037026 DOI: 10.3857/roj.2017.00458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
415 Zhao Q, Hu G, Xiao W, Chen Y, Shen M, Tang Q, Ning X. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study. Medicine (Baltimore) 2017;96:e7920. [PMID: 28858114 DOI: 10.1097/MD.0000000000007920] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
416 Rühle A, Perez RL, Glowa C, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE, Nicolay NH. Cisplatin radiosensitizes radioresistant human mesenchymal stem cells. Oncotarget 2017;8:87809-20. [PMID: 29152122 DOI: 10.18632/oncotarget.21214] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
417 Luo LL, Xi M, Yang YD, Li QQ, Zhao L, Zhang P, Liu SL, Liu MZ. Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:3441-7. [PMID: 29151927 DOI: 10.7150/jca.21131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
418 Tseng J, Posner MC. An Update on Randomized Clinical Trials in Gastric Cancer. Surg Oncol Clin N Am 2017;26:621-45. [PMID: 28923222 DOI: 10.1016/j.soc.2017.05.003] [Reference Citation Analysis]
419 Ji Y, Du X, Tian Y, Sheng L, Cheng L, Chen Y, Qiu G, Zhou X, Bao W, Zhang D, Chen M. A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Oncotarget 2017;8:83022-9. [PMID: 29137320 DOI: 10.18632/oncotarget.20938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
420 Morita M, Egashira A, Nakaji YU, Kagawa M, Sugiyama M, Yoshida D, Ota M, Ikebe M, Masuda M, Inoue Y, Kunitake N, Toh Y. Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer. In Vivo 2017;31:909-16. [PMID: 28882958 DOI: 10.21873/invivo.11146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
421 Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J, Crosby T. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017;125:154-9. [PMID: 28893415 DOI: 10.1016/j.radonc.2017.08.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
422 Jia Y, Xiao Z, Jiang W, Chen G, Wang Z. Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. Thorac Cancer 2017;8:592-9. [PMID: 28857475 DOI: 10.1111/1759-7714.12488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
423 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
424 Tamtai A, Jiarpinitnun C, Hiranyatheb P, Unwanatham N, Sirachainun E, Supsamutchai C, Pattaranutaporn P, Ngamphaiboon N. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1017-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
425 Chen J, Su T, Lin Y, Wang B, Li J, Pan J, Chen C. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma. Clin Transl Oncol. 2018;20:411-419. [PMID: 28779422 DOI: 10.1007/s12094-017-1734-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
426 Zhang W, Wang Q, Li T, Lv J, Liu H, Jia X, Liu B, Fan Y, Wang Y, Wang J, Wu L, Lang J. External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. J Contemp Brachytherapy 2017;9:330-7. [PMID: 28951752 DOI: 10.5114/jcb.2017.69334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
427 Zhang W, Li H, Chen X, Su M, Lin R, Zou C. Phase II study of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophagealcancer patients. Br J Radiol 2017;90:20170328. [PMID: 28749231 DOI: 10.1259/bjr.20170328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
428 Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer 2017;117:648-55. [PMID: 28728163 DOI: 10.1038/bjc.2017.225] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
429 Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ozawa S, Abe T, Nakamura K, Kato K, Ando N, Kitagawa Y. Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer: Exploratory Analysis of JCOG9907.Ann Surg. 2017;265:1152-1157. [PMID: 27280509 DOI: 10.1097/SLA.0000000000001828] [Cited by in Crossref: 78] [Cited by in F6Publishing: 101] [Article Influence: 15.6] [Reference Citation Analysis]
430 Tang HR, Ma HF, An SM, Badakhshi H, Deng JY, Zhang JH, Chen Y, Zhang Z, Guo XM, Jiang GL. A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma. Am J Clin Oncol. 2016;39:350-354. [PMID: 24732811 DOI: 10.1097/coc.0000000000000069] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
431 Wu P, Liu J, Sun X, Li X, Xing L, Yu J. Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model. Oncotarget 2017;8:63871-80. [PMID: 28969036 DOI: 10.18632/oncotarget.19151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
432 Deng Y, Bian C, Tao H, Zhang H. Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Oncotarget 2017;8:79662-9. [PMID: 29108346 DOI: 10.18632/oncotarget.19030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
433 Jing Z, Chen T, Zhang X, Wu S. Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer. Cancer Sci 2017;108:1828-33. [PMID: 28665042 DOI: 10.1111/cas.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
434 Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis 2017;9:S792-8. [PMID: 28815076 DOI: 10.21037/jtd.2017.05.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
435 So B, Marcu LG, Olver I, Gowda R, Bezak E. Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas. Acta Oncol 2017;56:899-908. [PMID: 28375694 DOI: 10.1080/0284186X.2017.1307518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
436 Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC. What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget 2017;8:89095-107. [PMID: 29179502 DOI: 10.18632/oncotarget.18760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
437 Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 2017;99:667-76. [PMID: 29280461 DOI: 10.1016/j.ijrobp.2017.06.2450] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
438 Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebersold DM, Ozsahin M. Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. Radiat Oncol 2017;12:97. [PMID: 28615060 DOI: 10.1186/s13014-017-0834-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
439 Lin WC, Ding YF, Hsu HL, Chang JH, Yuan KS, Wu ATH, Chow JM, Chang CL, Chen SU, Wu SY. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma. Cancer 2017;123:3904-15. [PMID: 28608916 DOI: 10.1002/cncr.30823] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
440 Chen SB, Yang XH, Weng HR, Liu DT, Li H, Chen YP. Clinicopathological features and surgical treatment of cervical oesophageal cancer. Sci Rep 2017;7:3272. [PMID: 28607370 DOI: 10.1038/s41598-017-03593-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
441 Klevebro F, Ekman S, Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article. Surg Oncol. 2017;26:290-295. [PMID: 28807249 DOI: 10.1016/j.suronc.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
442 Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2017;99:407-16. [PMID: 28871991 DOI: 10.1016/j.ijrobp.2017.05.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
443 Fang M, Song T, Liang X, Lv S, Li J, Xu H, Luo L, Jia Y. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:37080-90. [PMID: 28415745 DOI: 10.18632/oncotarget.16180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
444 Ng J, Lee P. The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. Hematology/Oncology Clinics of North America 2017;31:453-68. [DOI: 10.1016/j.hoc.2017.01.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
445 Nishida T, Takeno S, Nakashima K, Kariya M, Inatsu H, Kitamura K, Nanashima A. Salvage photodynamic therapy accompanied by extended lymphadenectomy for advanced esophageal carcinoma: A case report. Int J Surg Case Rep 2017;36:155-60. [PMID: 28587972 DOI: 10.1016/j.ijscr.2017.05.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
446 Tan B, Wang J, Song Q, Wang N, Jia Y, Wang C, Yao B, Liu Z, Zhang X, Cheng Y. Prognostic value of PAX9 in patients with esophageal squamous cell carcinoma and its prediction value to radiation sensitivity. Mol Med Rep 2017;16:806-16. [PMID: 28560390 DOI: 10.3892/mmr.2017.6626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
447 Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther 2017;17:635-46. [PMID: 28503964 DOI: 10.1080/14737140.2017.1331130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
448 Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286-94. [PMID: 29113302 DOI: 10.18632/oncotarget.17925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
449 Huang BT, Wu LL, Guo LJ, Xu LY, Huang RH, Lin PX, Chen JZ, Li DR, Chen CZ. Radiobiological evaluation of simultaneously dose-escalated versus non-escalated intensity-modulated radiation therapy for patients with upper thoracic esophageal cancer. Onco Targets Ther 2017;10:2209-17. [PMID: 28458564 DOI: 10.2147/OTT.S132388] [Reference Citation Analysis]
450 Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. J Thorac Oncol 2017;12:1152-60. [PMID: 28455149 DOI: 10.1016/j.jtho.2017.04.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
451 Kumaran D, John S, Isiah R, Das S. Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. J Gastrointest Cancer 2016;47:313-7. [PMID: 27146042 DOI: 10.1007/s12029-016-9825-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
452 Wang X, Miao C, Chen Z, Li W, Yuan S, Yu J, Hu X. Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis. Onco Targets Ther 2017;10:2087-95. [PMID: 28442917 DOI: 10.2147/OTT.S130285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
453 Li Z, Zhang P, Ma Q, Wang D, Zhou T. Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. Mol Clin Oncol 2017;6:743-7. [PMID: 28515926 DOI: 10.3892/mco.2017.1222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
454 Ku GY. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical Oncology Clinics of North America 2017;26:241-56. [DOI: 10.1016/j.soc.2016.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
455 Safaei AM, Ghalehtaki R, Khanjani N, Farazmand B, Babaei M, Esmati E. High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results. J Contemp Brachytherapy 2017;9:30-5. [PMID: 28344601 DOI: 10.5114/jcb.2017.65147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
456 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
457 Xia Y, Li YH, Chen Y, Zhang JH, Liu Q, Deng JY, Ai TS, Zhu HT, Fan JH, Badakhshi H, Zhao KL. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma. Radiat Oncol 2017;12:47. [PMID: 28270162 DOI: 10.1186/s13014-017-0785-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
458 Ng SP, Tan J, Osbourne G, Williams L, Bressel MAB, Hicks RJ, Lau EWF, Chu J, Ngan SYK, Leong T. Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Clin Transl Radiat Oncol 2017;2:76-82. [PMID: 29658005 DOI: 10.1016/j.ctro.2017.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
459 Cong L, Hu L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2017;46:75-79. [PMID: 28268208 DOI: 10.1016/j.intimp.2017.02.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
460 Wald O, Smaglo B, Mok H, Groth SS. Future directions in esophageal cancer therapy. Ann Cardiothorac Surg 2017;6:159-66. [PMID: 28447005 DOI: 10.21037/acs.2017.02.01] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
461 Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, Komaki R, Lin SH. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. Int J Radiat Oncol Biol Phys 2017;98:811-9. [PMID: 28602412 DOI: 10.1016/j.ijrobp.2017.02.097] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
462 Swisher SG, Marks J, Rice D. Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation. Ann Cardiothorac Surg 2017;6:144-51. [PMID: 28447003 DOI: 10.21037/acs.2017.03.02] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
463 Wang H, Li G, Chen L, Duan Y, Zou C, Hu C. Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients. J Thorac Dis 2017;9:646-54. [PMID: 28449472 DOI: 10.21037/jtd.2017.03.105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
464 Koide Y, Kodaira T, Tachibana H, Tomita N, Makita C, Itoh M, Abe T, Muro K, Tajika M, Niwa Y, Itoh Y, Naganawa S. Clinical outcome of definitive radiation therapy for superficial esophageal cancer. Japanese Journal of Clinical Oncology 2017;47:393-400. [DOI: 10.1093/jjco/hyx021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
465 Takeuchi H, Miyata H, Ozawa S, Udagawa H, Osugi H, Matsubara H, Konno H, Seto Y, Kitagawa Y. Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan. Ann Surg Oncol 2017;24:1821-7. [DOI: 10.1245/s10434-017-5808-4] [Cited by in Crossref: 101] [Cited by in F6Publishing: 124] [Article Influence: 20.2] [Reference Citation Analysis]
466 Jing W, Guo H, Kong L, Zhang Y, Wang H, An C, Zhu H, Yu J. Clinical outcomes of elderly patients (≥70 years) with resectable esophageal squamous cell carcinoma who underwent esophagectomy or chemoradiotherapy: A retrospective analysis from a single cancer institute. Medicine (Baltimore) 2016;95:e5630. [PMID: 27977606 DOI: 10.1097/MD.0000000000005630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
467 Liu X, Li M, Zhao F, Zhu Y, Luo Y, Kong L, Zhu H, Zhang Y, Shi F, Yu J. The lymphocyte-monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy. Onco Targets Ther 2017;10:871-7. [PMID: 28243122 DOI: 10.2147/OTT.S124915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
468 Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Br J Cancer 2017;116:709-16. [PMID: 28196063 DOI: 10.1038/bjc.2017.21] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
469 Chun SG, Skinner HD, Minsky BD. Radiation Therapy for Locally Advanced Esophageal Cancer. Surg Oncol Clin N Am 2017;26:257-76. [PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
470 Li T, Zhang W, Lv J, Liu H, Wang Q, Jia X, Liu B, Lang J. Safety and outcome of external beam radiation and neutron brachytherapy in elderly patients with esophageal squamous cell cancer. J Contemp Brachytherapy 2017;9:36-43. [PMID: 28344602 DOI: 10.5114/jcb.2017.65839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
471 Oh D, Noh JM, Nam H, Lee H, Kim TG, Ahn YC. High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma. Medicine (Baltimore) 2016;95:e4591. [PMID: 27537591 DOI: 10.1097/MD.0000000000004591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
472 Jeene PM, Versteijne E, van Berge Henegouwen MI, Bergmann JJ, Geijsen ED, Muller K, van Laarhoven HW, Hulshof MC. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment. Dis Esophagus 2017;30:1-5. [PMID: 27766725 DOI: 10.1111/dote.12539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
473 Hu Y, Li Z, Mi DH, Cao N, Zu SW, Wen ZZ, Yu XL, Qu Y. Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis. J Clin Pharm Ther 2017;42:155-64. [PMID: 28120520 DOI: 10.1111/jcpt.12498] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
474 Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. World J Gastroenterol 2017; 23(3): 540-546 [PMID: 28210091 DOI: 10.3748/wjg.v23.i3.540] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
475 Matzenauer M, Vrána D, Vlachová Z, Aujesky R, Vrba R, Neoral C, Melichar B. Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. Oncol Lett 2017;13:1807-10. [PMID: 28454327 DOI: 10.3892/ol.2017.5605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
476 Yin H, E M, Zhang H, Wang C. The outcomes of radiotherapy and factors that predict overall survival in elderly patients with esophageal squamous cell carcinoma. Clin Transl Oncol 2017;19:742-9. [DOI: 10.1007/s12094-016-1603-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
477 Ma L, Luo GY, Ren YF, Qiu B, Yang H, Xie CX, Liu SR, Liu SL, Chen ZL, Li Q, Fu JH, Liu MZ, Hu YH, Ye WF, Liu H. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae. Chin J Cancer. 2017;36:8. [PMID: 28077159 DOI: 10.1186/s40880-016-0171-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
478 Jeene PM, Versteijne E, van Berge Henegouwen MI, Bergmann JJ, Geijsen ED, van Laarhoven HW, Hulshof MC. Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. Acta Oncol 2017;56:33-8. [PMID: 27842455 DOI: 10.1080/0284186X.2016.1240880] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
479 Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D, Sahu A, Shah S, Ghosh-Laskar S, Patil PS, Mehta SA, Jambhekar N, Mahajan A, Purandare N. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncol Res 2016;23:183-95. [PMID: 27053347 DOI: 10.3727/096504016X14537290676865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
480 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 106] [Article Influence: 13.8] [Reference Citation Analysis]
481 Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X, Luo J. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2017;13:704-714. [PMID: 28356949 DOI: 10.3892/ol.2016.5496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
482 Wang YD, Lu N. Consensus and controversies on dose and target volume of three-dimensional conformal radiotherapy for esophageal carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(34): 4531-4536 [DOI: 10.11569/wcjd.v24.i34.4531] [Reference Citation Analysis]
483 Zenda S, Kojima T, Kato K, Izumi S, Ozawa T, Kiyota N, Katada C, Tsushima T, Ito Y, Akimoto T, Hasegawa Y, Kanamaru M, Daiko H. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. International Journal of Radiation Oncology*Biology*Physics 2016;96:976-84. [DOI: 10.1016/j.ijrobp.2016.08.045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
484 Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol 2016;18:1179-86. [PMID: 27900538 DOI: 10.1007/s12094-016-1577-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
485 Garcia B, Goodman KA, Cambridge L, Dunphy M, Wu AJ. Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation. Radiat Oncol 2016;11:156. [PMID: 27887643 DOI: 10.1186/s13014-016-0731-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
486 Song T, Zhang X, Fang M, Zhao R, Wu S. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial. Cancer Med 2016;5:3371-7. [PMID: 27925455 DOI: 10.1002/cam4.897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
487 Satomura H, Nakajima M, Sasaki K, Yamaguchi S, Domeki Y, Takahashi M, Muroi H, Kubo T, Kikuchi M, Otomo H, Ihara K, Kato H. Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma. Int Surg 2015;100:1153-8. [PMID: 26414837 DOI: 10.9738/INTSURG-D-14-00233.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
488 Morita K, Miyazaki S, Numako C, Ikeno S, Sasaki R, Nishimura Y, Ogino C, Kondo A. Characterization of titanium dioxide nanoparticles modified with polyacrylic acid and H2O2 for use as a novel radiosensitizer. Free Radic Res 2016;50:1319-28. [PMID: 27778515 DOI: 10.1080/10715762.2016.1241879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
489 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics 2016;13:1041-53. [PMID: 27718753 DOI: 10.1080/14789450.2016.1246189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
490 Farinella E, Safar A, Nasser HA, Bouazza F, Liberale G, Paesmans M, Marechal R, Van Laethem JL, Hendlisz A, VanHoutte P, El Nakadi I. Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer. J Surg Oncol 2016;114:833-7. [PMID: 27778349 DOI: 10.1002/jso.24429] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
491 Mofid B, Razzaghdoust A, Kashi AS, Mirzaei HR. A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus. Electron Physician 2016;8:3069-75. [PMID: 27957305 DOI: 10.19082/3069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
492 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
493 Wang L, Zhu C, Ma X, Shen K, Li H, Hu Y, Guo L, Zhang J, Li P. Impact of enhanced recovery program on patients with esophageal cancer in comparison with traditional care. Support Care Cancer 2017;25:381-9. [DOI: 10.1007/s00520-016-3410-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
494 Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol 2017;12:368-74. [PMID: 27729298 DOI: 10.1016/j.jtho.2016.10.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
495 Xing J, Luo Y, Wang X, Gao M, Sun M, Ding X, Fan T, Yu J. Anatomic distribution of supraclavicular lymph node in patients with esophageal cancer. Onco Targets Ther 2016;9:5803-8. [PMID: 27703379 DOI: 10.2147/OTT.S111800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
496 Kim HJ, Suh YG, Lee YC, Lee SK, Shin SK, Cho BC, Lee CG. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Res Treat 2017;49:669-77. [PMID: 27737537 DOI: 10.4143/crt.2016.354] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
497 Takebayashi K, Tsubosa Y, Kamijo T, Iida Y, Imai A, Nagaoka M, Kitani T, Niihara M, Booka E, Shimada A, Nakagawa M, Onitsuka T. Comparison of Salvage Total Pharyngolaryngectomy and Cervical Esophagectomy Between Hypopharyngeal Cancer and Cervical Esophageal Cancer. Ann Surg Oncol 2017;24:778-84. [PMID: 27714538 DOI: 10.1245/s10434-016-5474-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
498 Sio TT, Wilson ZC, Stauder MC, Bhatia S, Martenson JA, Quevedo JF, Schomas DA, Miller RC. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. American Journal of Clinical Oncology 2016;39:448-52. [DOI: 10.1097/coc.0000000000000089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
499 Jamorabo DS, Lin SH, Jabbour SK. Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. Seminars in Radiation Oncology 2016;26:307-19. [DOI: 10.1016/j.semradonc.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
500 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
501 Xu Y, Zheng Y, Sun X, Yu X, Gu J, Wu W, Zhang G, Hu J, Sun W, Mao W. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. Oncotarget 2015;6:38429-39. [PMID: 26392415 DOI: 10.18632/oncotarget.5193] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
502 Lv S, Fang M, Yang J, Zhan W, Jia Y, Xu H, Song T. Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer. Onco Targets Ther 2016;9:5389-97. [PMID: 27660461 DOI: 10.2147/OTT.S107668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
503 Kapoor R, Bansal A, Kumar S, Miriyala RT. Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. Indian J Palliat Care 2016;22:288-94. [PMID: 27559257 DOI: 10.4103/0973-1075.185037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
504 Yang Z, Dai H, Lv D, Feng AL, Shu W, Han J. Clinical observation of gene expression-guided chemoradiation therapy for nonsurgical esophageal squamous cell carcinoma patients: a retrospective analysis of 36 cases. Onco Targets Ther 2016;9:4561-8. [PMID: 27524911 DOI: 10.2147/OTT.S105221] [Reference Citation Analysis]
505 Ito H, Itasaka S, Sakanaka K, Araki N, Mizowaki T, Hiraoka M. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res 2017;58:106-13. [PMID: 27475126 DOI: 10.1093/jrr/rrw078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
506 De Santis MC, Nardone L, Diletto B, Canna R, Dispinzieri M, Marino L, Lozza L, Valentini V. Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer. Br J Radiol 2016;89:20160264. [PMID: 27452265 DOI: 10.1259/bjr.20160264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
507 Berry MF. The Role of Induction Therapy for Esophageal Cancer. Thorac Surg Clin 2016;26:295-304. [PMID: 27427524 DOI: 10.1016/j.thorsurg.2016.04.006] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
508 Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database. PLoS One 2016;11:e0158916. [PMID: 27428362 DOI: 10.1371/journal.pone.0158916] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
509 Ohba A, Kato K, Ito Y, Katada C, Ishiyama H, Yamamoto S, Ura T, Kodaira T, Kudo S, Tamaki Y. Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial. Adv Radiat Oncol. 2016;1:230-236. [PMID: 28740892 DOI: 10.1016/j.adro.2016.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
510 Sasaki Y, Kato K. Chemoradiotherapy for esophageal squamous cell cancer. Jpn J Clin Oncol 2016;46:805-10. [PMID: 27380810 DOI: 10.1093/jjco/hyw082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
511 Hu G, Wang Z, Wang Y, Zhang Q, Tang N, Guo J, Liu L, Han X. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. Drug Des Devel Ther 2016;10:2129-36. [PMID: 27445460 DOI: 10.2147/DDDT.S105441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
512 Hulshof MC, van Laarhoven HW. Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. Best Pract Res Clin Gastroenterol 2016;30:551-63. [PMID: 27644904 DOI: 10.1016/j.bpg.2016.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
513 Uchinami Y, Myojin M, Takahashi H, Harada K, Shimizu S, Hosokawa M. Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa. Radiat Oncol 2016;11:84. [PMID: 27328734 DOI: 10.1186/s13014-016-0660-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
514 Cox S, Powell C, Carter B, Hurt C, Mukherjee S, Crosby TD. Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. Br J Cancer 2016;115:172-7. [PMID: 27328311 DOI: 10.1038/bjc.2016.129] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
515 Créhange G, Conroy T. The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future? J Thorac Dis 2016;8:1014-8. [PMID: 27293806 DOI: 10.21037/jtd.2016.03.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
516 Chen Y, Zhang Z, Jiang G, Zhao K. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy. J Thorac Dis 2016;8:1155-61. [PMID: 27293832 DOI: 10.21037/jtd.2016.04.08] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
517 Zhang X, Yu J, Li M, Zhu H. Details of out-field regional recurrence after involved-field irradiation with concurrent chemotherapy for locally advanced esophageal squamous cell carcinoma. Onco Targets Ther 2016;9:3049-57. [PMID: 27284256 DOI: 10.2147/OTT.S100946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
518 Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology 2016;102:37-46. [DOI: 10.1016/j.critrevonc.2016.03.014] [Cited by in Crossref: 121] [Cited by in F6Publishing: 135] [Article Influence: 20.2] [Reference Citation Analysis]
519 Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes. The Annals of Thoracic Surgery 2016;101:2148-54. [DOI: 10.1016/j.athoracsur.2015.12.056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
520 Sun X, Han S, Gu F, Lin G, Wang Z, Wang Y, Xu Y. A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma. J Cancer 2016;7:1066-73. [PMID: 27326249 DOI: 10.7150/jca.13547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
521 Machiels M, Wouterse SJ, Geijsen ED, van Os RM, Bennink RJ, van Laarhoven HW, Hulshof MC. Distribution of lymph node metastases on FDG-PET/CT in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy. J Med Imaging Radiat Oncol 2016;60:520-7. [PMID: 27197751 DOI: 10.1111/1754-9485.12474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
522 Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78:91-99. [PMID: 27193097 DOI: 10.1007/s00280-016-3062-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
523 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
524 Hoeben A, Polak J, Van De Voorde L, Hoebers F, Grabsch HI, de Vos-Geelen J. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol. 2016;27:1664-1674. [PMID: 27117535 DOI: 10.1093/annonc/mdw183] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
525 Ji Y, Qiu G, Sheng L, Sun X, Zheng Y, Chen M, Du X. A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis 2016;8:451-8. [PMID: 27076940 DOI: 10.21037/jtd.2016.02.70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
526 Li M, Zhao F, Zhang X, Shi F, Zhu H, Han A, Zhang Y, Kong L, Yu J. Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus. Curr Oncol 2016;23:e131-7. [PMID: 27122981 DOI: 10.3747/co.23.2846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
527 Fulton BA, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A, Grose D. Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. J Gastrointest Oncol 2016;7:166-72. [PMID: 27034782 DOI: 10.3978/j.issn.2078-6891.2015.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
528 Booka E, Tsubosa Y, Niihara M, Takagi W, Takebayashi K, Shimada A, Kitani T, Nagaoka M, Imai A, Kamijo T, Iida Y, Onitsuka T, Nakagawa M, Takeuchi H, Kitagawa Y. Risk factors for complications after pharyngolaryngectomy with total esophagectomy. Esophagus 2016;13:317-22. [PMID: 27695394 DOI: 10.1007/s10388-016-0533-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
529 Chen JL, Chen JP, Huang YS, Tsai YC, Tsai MH, Jaw FS, Cheng JC, Kuo SH, Shieh MJ. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition. Strahlenther Onkol 2016;192:260-8. [PMID: 26952039 DOI: 10.1007/s00066-016-0951-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
530 Sakanaka K, Ishida Y, Itasaka S, Ezoe Y, Aoyama I, Miyamoto S, Horimatsu T, Muto M, Hiraoka M. Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy. Int J Clin Oncol 2016;21:899-908. [PMID: 26936851 DOI: 10.1007/s10147-016-0967-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
531 Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais M, Artru P, Blondin V, Dupuis O, Abdiche MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A. Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX. European Journal of Cancer 2016;56:115-21. [DOI: 10.1016/j.ejca.2015.12.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
532 Zhang H, Luo H, Hu Z, Peng J, Jiang Z, Song T, Wu B, Yue J, Zhou R, Xie R, Chen T, Wu S. Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation. Oncotarget 2015;6:6218-34. [PMID: 25749038 DOI: 10.18632/oncotarget.3358] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
533 Tanaka Y, Yoshida K, Yamada A, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K, Miyazaki T. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2016;77:1143-52. [PMID: 26896963 DOI: 10.1007/s00280-016-2985-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
534 Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2016;89:20150476. [PMID: 26891913 DOI: 10.1259/bjr.20150476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
535 Franco P, Fiorentino A, Dionisi F, Fiore M, Chiesa S, Vagge S, Cellini F, Caravatta L, Tombolini M, De Rose F, Meattini I, Mortellaro G, Apicella G, Marino L, Greto D. Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting. Tumori 2016;102:459-71. [DOI: 10.5301/tj.5000525] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
536 Li M, Zhang X, Zhao F, Luo Y, Kong L, Yu J. Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiat Oncol 2016;11:18. [PMID: 26846932 DOI: 10.1186/s13014-016-0589-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
537 Takada A, Nakamura T, Takayama K, Makita C, Suzuki M, Azami Y, Kato T, Tsukiyama I, Hareyama M, Kikuchi Y, Daimon T, Toyomasu Y, Ii N, Nomoto Y, Sakuma H, Fuwa N. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Cancer Med 2016;5:506-15. [PMID: 26806272 DOI: 10.1002/cam4.607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
538 Chen X, Deng L, Jiang X, Wu T. Chinese herbal medicine for oesophageal cancer. Cochrane Database Syst Rev 2016;:CD004520. [PMID: 26799001 DOI: 10.1002/14651858.CD004520.pub7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
539 Dong Y, Guan H, Huang W, Zhang Z, Zhao D, Liu Y, Zhou T, Li B. Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases. J Thorac Dis 2015;7:2313-20. [PMID: 26793353 DOI: 10.3978/j.issn.2072-1439.2015.12.10] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
540 Kamran SC, Hong TS, Wo JY. Advances in the Management of Gastric and Gastroesophageal Cancers. Curr Oncol Rep 2016;18. [DOI: 10.1007/s11912-015-0493-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
541 Kataoka K, Takeuchi H, Mizusawa J, Ando M, Tsubosa Y, Koyanagi K, Daiko H, Matsuda S, Nakamura K, Kato K, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol 2016;46:174-7. [PMID: 26732383 DOI: 10.1093/jjco/hyv178] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
542 Han D, Yuan Y, Song X, Yu Y, Yu J. What Is the Appropriate Clinical Target Volume for Esophageal Squamous Cell Carcinoma? Debate and Consensus Based on Pathological and Clinical Outcomes. J Cancer 2016;7:200-6. [PMID: 26819644 DOI: 10.7150/jca.13873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
543 Eads JR, Beumer JH, Negrea L, Holleran JL, Strychor S, Meropol NJ. A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 2016;77:333-8. [PMID: 26687170 DOI: 10.1007/s00280-015-2939-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
544 Deng J, Wang C, Shi X, Jiang G, Wang Y, Liu Y, Zhao K. Reduced toxicity with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy compared with conventional two-dimensional radiotherapy for esophageal squamous cell carcinoma: a secondary analysis of data from four prospective clinical: 3DCRT/IMRT reduces toxicities in ESCC. Dis Esophagus 2016;29:1121-7. [DOI: 10.1111/dote.12435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
545 Jing W, Zhu H, Guo H, Zhang Y, Shi F, Han A, Li M, Kong L, Yu J. Feasibility of Elective Nodal Irradiation (ENI) and Involved Field Irradiation (IFI) in Radiotherapy for the Elderly Patients (Aged ≥ 70 Years) with Esophageal Squamous Cell Cancer: A Retrospective Analysis from a Single Institute. PLoS One 2015;10:e0143007. [PMID: 26636574 DOI: 10.1371/journal.pone.0143007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
546 Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016;10:383-392. [PMID: 26560689 DOI: 10.1586/17474124.2016.1116936] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
547 Ono T, Nakamura T, Azami Y, Yamaguchi H, Hayashi Y, Suzuki M, Hatayama Y, Tsukiyama I, Hareyama M, Kikuchi Y, Nemoto K. Clinical results of proton beam therapy for twenty older patients with esophageal cancer. Radiol Oncol 2015;49:371-8. [PMID: 26834524 DOI: 10.1515/raon-2015-0034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
548 Anandavadivelan P, Lagergren P. Cachexia in patients with oesophageal cancer. Nat Rev Clin Oncol 2016;13:185-98. [PMID: 26573424 DOI: 10.1038/nrclinonc.2015.200] [Cited by in Crossref: 77] [Cited by in F6Publishing: 103] [Article Influence: 11.0] [Reference Citation Analysis]
549 Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y, Li G, Zhu J, Wu Y, Fan M, Deng W, Wei Q, Zhang Z. TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. Medicine (Baltimore) 2015;94:e1955. [PMID: 26559268 DOI: 10.1097/MD.0000000000001955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
550 Porteous GH, Neal JM, Slee A, Schmidt H, Low DE. A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomes. Reg Anesth Pain Med 2015;40:139-49. [PMID: 25658034 DOI: 10.1097/AAP.0000000000000197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
551 Booka E, Takeuchi H, Nishi T, Matsuda S, Kaburagi T, Fukuda K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Omori T, Kitagawa Y. The Impact of Postoperative Complications on Survivals After Esophagectomy for Esophageal Cancer. Medicine (Baltimore) 2015;94:e1369. [PMID: 26287423 DOI: 10.1097/MD.0000000000001369] [Cited by in Crossref: 93] [Cited by in F6Publishing: 111] [Article Influence: 13.3] [Reference Citation Analysis]
552 Umezawa R, Jingu K, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K, Ariga H, Nemoto K, Yamada S. Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols. BMC Cancer 2015;15:813. [PMID: 26506988 DOI: 10.1186/s12885-015-1836-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
553 Nakajima M, Domeki Y, Satomura H, Takahashi M, Sugawara A, Muroi H, Sasaki K, Yamaguchi S, Miyazaki T, Kuwano H, Kato H. Salvage lymphadenectomy for recurrent esophageal cancer after chemoradiotherapy. Int Surg 2014;99:452-7. [PMID: 25058783 DOI: 10.9738/INTSURG-D-13-00261.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
554 Song T, Zhang X, Fang M, Wu S. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer. Onco Targets Ther. 2015;8:3087-3094. [PMID: 26543377 DOI: 10.2147/ott.s92537] [Cited by in Crossref: 8] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
555 Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol 2015;6:516-23. [PMID: 26487946 DOI: 10.3978/j.issn.2078-6891.2015.040] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
556 Bronson NW, Diggs BS, Bakis G, Gatter KM, Sheppard BC, Hunter JG, Dolan JP. Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy. J Gastrointest Surg 2015;19:2105-10. [DOI: 10.1007/s11605-015-2944-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
557 Chen S, Weng H, Wang G, Liu D, Li H, Zhang H, Chen Y. The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2016;142:277-86. [DOI: 10.1007/s00432-015-2041-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
558 Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2:831-838. [PMID: 25187273 DOI: 10.1158/2326-6066.cir-14-0069] [Cited by in Crossref: 190] [Cited by in F6Publishing: 191] [Article Influence: 27.1] [Reference Citation Analysis]
559 Wang J, Yu Y, Zhan BH, Ge N, Zhou Q. Radiotherapy concurrent with paclitaxel plus cisplatin vs 5-fluorouracil plus cisplatin for esophageal cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(24): 3904-3908 [DOI: 10.11569/wcjd.v23.i24.3904] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
560 Kumagai K, Mariosa D, Tsai JA, Nilsson M, Ye W, Lundell L, Rouvelas I. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. Dis Esophagus 2016;29:734-9. [PMID: 26316181 DOI: 10.1111/dote.12399] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
561 Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, Nakagawa K. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol 2015;10:171. [PMID: 26269033 DOI: 10.1186/s13014-015-0482-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
562 Cooper BT, Sanfilippo NJ. Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol 2015; 6(4): 35-42 [PMID: 26266099 DOI: 10.5306/wjco.v6.i4.35] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
563 Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther 2015;15:1157-69. [PMID: 26235427 DOI: 10.1586/14737140.2015.1074041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
564 Peyraga G, Capitain O, Rousseau D, Rio E, Septans AL, Baton O, Marquis A, Trémolières P, Gustin P, Ménager É, Branger F, Bressolette M, Deutsch É, Paumier A. [Are extensive fields useful for radiotherapy of esophageal cancer?]. Cancer Radiother 2015;19:313-21. [PMID: 26232314 DOI: 10.1016/j.canrad.2015.03.011] [Reference Citation Analysis]
565 Bednarek C, Crehange G, Quivrin M, Cueff A, Vulquin N, Chevalier C, Cerda T, Petegnief Y, Mazoyer F, Maingon P, Bosset JF, Servagi Vernat S. Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer: A posteriori analysis of the dose distribution in the sites of loco-regional relapse. Radiotherapy and Oncology 2015;116:252-6. [DOI: 10.1016/j.radonc.2015.07.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
566 Akutsu Y, Kono T, Uesato M, Hoshino I, Murakami K, Aoyagi T, Ota T, Toyozumi T, Suito H, Kobayashi H, Harada R, Uno T, Matsubara H. Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor? World J Surg 2014;38:2891-7. [PMID: 24952078 DOI: 10.1007/s00268-014-2668-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
567 Lin JC, Tsai JT, Chang CC, Jen YM, Li MH, Liu WH. Comparing treatment plan in all locations of esophageal cancer: volumetric modulated arc therapy versus intensity-modulated radiotherapy. Medicine (Baltimore) 2015;94:e750. [PMID: 25929910 DOI: 10.1097/MD.0000000000000750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
568 Markar S, Gronnier C, Duhamel A, Pasquer A, Théreaux J, du Rieu MC, Lefevre JH, Turner K, Luc G, Mariette C. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? J Clin Oncol 2015;33:3866-73. [PMID: 26195702 DOI: 10.1200/JCO.2014.59.9092] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 14.3] [Reference Citation Analysis]
569 Gaitonde SG, Hanseman DJ, Wima K, Sutton JM, Wilson GC, Sussman JJ, Ahmad SA, Shah SA, Abbott DE. Resource utilization in esophagectomy: When higher costs are associated with worse outcomes: Resource Utilization in Esophagectomy. J Surg Oncol 2015;112:51-5. [DOI: 10.1002/jso.23958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
570 Nishimura Y, Jingu K, Itasaka S, Negoro Y, Murakami Y, Karasawa K, Kawaguchi G, Isohashi F, Kobayashi M, Itoh Y, Ariga T. Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG). Int J Clin Oncol 2016;21:88-94. [PMID: 26178368 DOI: 10.1007/s10147-015-0872-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
571 Plastaras JP, Dionisi F, Wo JY. Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers. Cancer J 2014;20:378-86. [PMID: 25415682 DOI: 10.1097/PPO.0000000000000085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
572 Huang W, Huang Y, Sun J, Liu X, Zhang J, Zhou T, Zhang B, Li B. Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China. Radiother Oncol 2015;116:100-6. [PMID: 26142269 DOI: 10.1016/j.radonc.2015.06.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
573 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
574 Kato F, Takeuchi H, Matsuda S, Kawakubo H, Omori T, Kitagawa Y. Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study. Surg Today 2016;46:445-52. [DOI: 10.1007/s00595-015-1196-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
575 Bütof R, Hofheinz F, Zöphel K, Stadelmann T, Schmollack J, Jentsch C, Löck S, Kotzerke J, Baumann M, van den Hoff J. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. J Nucl Med 2015;56:1150-6. [DOI: 10.2967/jnumed.115.155309] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
576 Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015;10:e0128616. [PMID: 26046353 DOI: 10.1371/journal.pone.0128616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
577 Wang W, Wang Y, Lee C, Chang C, Lo J, Kuo Y, Hsu Y, Mo L. The impact of human papillomavirus infection on the survival and treatment response of patients with esophageal cancers: Human papillomavirus in esophageal SCC. Journal of Digestive Diseases 2015;16:256-63. [DOI: 10.1111/1751-2980.12236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
578 Chang CH, Liu SY, Chi CW, Yu HL, Chang TJ, Tsai TH, Lee TW, Chen YJ. External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics. Int J Nanomedicine 2015;10:3641-9. [PMID: 26056445 DOI: 10.2147/IJN.S80302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
579 He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 2014;9:1398-405. [PMID: 25122435 DOI: 10.1097/JTO.0000000000000267] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
580 Liu Q, Fu X, Yu W, Zhu Z, Zhang Y. Potential values of metabolic tumor volume and heterogeneity measured with 18F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy. Nuclear Medicine Communications 2015;36:423-9. [DOI: 10.1097/mnm.0000000000000267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
581 Lu W, Tan S, Chen W, Kligerman S, Feigenberg SJ, Zhang H, Suntharalingam M, Kang M, D'Souza WD. Pre-Chemoradiotherapy FDG PET/CT cannot Identify Residual Metabolically-Active Volumes within Individual Esophageal Tumors. J Nucl Med Radiat Ther 2015;6:226. [PMID: 26594591 DOI: 10.4172/2155-9619.1000226] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
582 Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, Debus J, Sterzing F. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res 2015;56:742-9. [PMID: 25907360 DOI: 10.1093/jrr/rrv022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
583 Chen Y, Li X, Guo L, Wu X, He C, Zhang S, Xiao Y, Yang Y, Hao D. Combining radiation with autophagy inhibition enhances suppression of tumor growth and angiogenesis in esophageal cancer. Mol Med Rep 2015;12:1645-52. [PMID: 25891159 DOI: 10.3892/mmr.2015.3623] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
584 Watanabe M, Mine S, Nishida K, Yamada K, Shigaki H, Matsumoto A, Sano T. Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery? Ann Surg Oncol 2015;22:4438-44. [PMID: 25862582 DOI: 10.1245/s10434-015-4556-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
585 Clavé P, Shaker R. Dysphagia: current reality and scope of the problem. Nat Rev Gastroenterol Hepatol 2015;12:259-70. [PMID: 25850008 DOI: 10.1038/nrgastro.2015.49] [Cited by in Crossref: 228] [Cited by in F6Publishing: 190] [Article Influence: 32.6] [Reference Citation Analysis]
586 Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR, Mamon HJ, Thomas CR Jr, Goodman KA. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. Int J Radiat Oncol Biol Phys 2015;92:911-20. [PMID: 26104943 DOI: 10.1016/j.ijrobp.2015.03.030] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
587 Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, Jeong JU, Song JY, Nam TK. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J 2015;33:12-20. [PMID: 25874173 DOI: 10.3857/roj.2015.33.1.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
588 Murakami Y, Takahashi I, Nishibuchi I, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y. Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0). Int J Clin Oncol 2015;20:897-904. [DOI: 10.1007/s10147-015-0819-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
589 Tian X, Zhou JG, Zeng Z, Shuai T, Yi LJ, Ma L, Wang Y, Cao H, Song GM. Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. Med Oncol 2015;32:127. [PMID: 25794489 DOI: 10.1007/s12032-015-0521-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
590 Lu JY, Cheung ML, Huang BT, Wu LL, Xie WJ, Chen ZJ, Li DR, Xie LX. Improving target coverage and organ-at-risk sparing in intensity-modulated radiotherapy for cervical oesophageal cancer using a simple optimisation method. PLoS One 2015;10:e0121679. [PMID: 25768733 DOI: 10.1371/journal.pone.0121679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
591 Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, Mizumoto M, Okumura T, Sakae T, Sakurai H. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res 2015;56:568-76. [PMID: 25755255 DOI: 10.1093/jrr/rrv001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
592 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
593 Cao C, Luo J, Gao L, Xu G, Yi J, Huang X, Wang K, Zhang S, Qu Y, Li S, Xiao J, Zhang Z. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma: clinical outcomes and patterns of failure. Eur Arch Otorhinolaryngol 2016;273:741-7. [DOI: 10.1007/s00405-015-3576-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
594 Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W, Tomita N, Nakagoe T, Shimada M, Sugihara K, Mori M. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259-266. [PMID: 24743609 DOI: 10.1097/sla.0000000000000644] [Cited by in Crossref: 275] [Cited by in F6Publishing: 291] [Article Influence: 39.3] [Reference Citation Analysis]
595 Cao C, Luo J, Gao L, Xu G, Yi J, Huang X, Wang K, Zhang S, Qu Y, Li S, Xiao J, Zhang Z. Definitive intensity-modulated radiotherapy compared with definitive conventional radiotherapy in cervical oesophageal squamous cell carcinoma. Radiol Med 2015;120:603-10. [PMID: 25644251 DOI: 10.1007/s11547-015-0510-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
596 Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015;6:53-9. [PMID: 25642338 DOI: 10.3978/j.issn.2078-6891.2014.099] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
597 Jiang L, Zhao X, Meng X, Yu J. Involved field irradiation for the treatment of esophageal cancer: Is it better than elective nodal irradiation? Cancer Letters 2015;357:69-74. [DOI: 10.1016/j.canlet.2014.11.045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
598 Yu W, Cai XW, Liu Q, Zhu ZF, Feng W, Zhang Q, Zhang YJ, Yao ZF, Fu XL. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer. Radiother Oncol 2015;114:195-200. [PMID: 25586952 DOI: 10.1016/j.radonc.2014.12.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
599 Stordeur S, Vlayen J, Vrijens F, Camberlin C, De Gendt C, Van Eycken E, Lerut T. Quality indicators for oesophageal and gastric cancer: a population-based study in Belgium, 2004-2008: Quality indicators for upper GI cancer. Eur J Cancer Care (Engl) 2015;24:376-86. [DOI: 10.1111/ecc.12279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
600 Aggarwal A, Harrison M, Glynne-jones R, Sinha-ray R, Cooper D, Hoskin P. Combination External Beam Radiotherapy and Intraluminal Brachytherapy for Non-radical Treatment of Oesophageal Carcinoma in Patients not Suitable for Surgery or Chemoradiation. Clinical Oncology 2015;27:56-64. [DOI: 10.1016/j.clon.2014.09.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
601 Luo C, Wen W, Lin F, Zhang X, Gu H, Wang S. Simplified aptamer-based colorimetric method using unmodified gold nanoparticles for the detection of carcinoma embryonic antigen. RSC Adv 2015;5:10994-9. [DOI: 10.1039/c4ra14833a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
602 Padmanaban S, Warren S, Walsh A, Partridge M, Hawkins MA. Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. Radiat Oncol 2014;9:286. [PMID: 25533761 DOI: 10.1186/s13014-014-0286-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
603 le Grange F, Wickers S, Warry A, Warrilow J, Bomanji J, Tobias JS. Defining the target in cancer of the oesophagus: direct radiotherapy planning with fluorodeoxyglucose positron emission tomography-computed tomography. Clin Oncol (R Coll Radiol) 2015;27:160-7. [PMID: 25540907 DOI: 10.1016/j.clon.2014.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
604 Galán M, Farran L, Aliste L, Hormigo G, Aranda H, Bettonica C, Boladeras AM, Botargues JM, Calvo M, Creus G, De Lama ME, Gornals JB, Mast R, Miró M, Paúles MJ, Robles J, Virgili N, Borràs JM. Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study. Clin Transl Oncol 2015;17:247-56. [DOI: 10.1007/s12094-014-1221-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
605 Ma K, Wang Q, Li T, Liu H, Liu B, Jia X, Li S, Lang J, Zhang M. A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. Radiat Oncol 2014;9:294. [PMID: 25515326 DOI: 10.1186/s13014-014-0294-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Alzahrani AM, Bazarbashi SN, Rahal MM, Al-Shehri AS, Aljubran AH, Kandil MS, Zekri JE, Al Olayan AA, Alsharm AA, Yamani NM, Alomary IS, Fagih MA; Saudi Oncology Society. Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. Saudi Med J 2014;35:1545-9. [PMID: 25491227] [Reference Citation Analysis]
607 Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423-429. [PMID: 25304796 DOI: 10.1016/j.ijrobp.2014.06.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
608 Stegeman H, Span PN, Kaanders JH, Bussink J. Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treatment Reviews 2014;40:1182-91. [DOI: 10.1016/j.ctrv.2014.09.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
609 Muijs CT, Beukema JC, Woutersen D, Mul VE, Berveling MJ, Pruim J, van der Jagt EJ, Hospers GA, Groen H, Plukker JT, Langendijk JA. Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Radiother Oncol 2014;113:188-92. [PMID: 25467002 DOI: 10.1016/j.radonc.2014.10.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
610 Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M, Sumita K, Tanigawa N. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol 2015;88:20140168. [PMID: 25429644 DOI: 10.1259/bjr.20140168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
611 Feng T, Li L, Ling S, Fan N, Fang M, Zhang H, Fang X, Lan W, Hou Z, Meng Q, Jin D, Xu F, Li Y. Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK. Biomed Pharmacother 2015;69:260-6. [PMID: 25661368 DOI: 10.1016/j.biopha.2014.11.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
612 Yamashita H, Omori M, Takenaka R, Okuma K, Kobayashi R, Ohtomo K, Nakagawa K. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study. Radiother Oncol 2014;113:182-7. [PMID: 25466372 DOI: 10.1016/j.radonc.2014.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
613 Dai T, Shah MA. Chemoradiation in oesophageal cancer. Best Pract Res Clin Gastroenterol 2015;29:193-209. [PMID: 25743466 DOI: 10.1016/j.bpg.2014.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
614 Liu M, Chen Y, Fu X, Zhao K, Jiang G. Proposed revision of CT-based cervical and thoracic lymph node levels for esophageal cancer in UICC 7th version. Radiotherapy and Oncology 2014;113:175-81. [DOI: 10.1016/j.radonc.2014.11.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
615 Liu M, Zhao K, Chen Y, Jiang GL. Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis. Radiat Oncol 2014;9:232. [PMID: 25344056 DOI: 10.1186/s13014-014-0232-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
616 Shaughnessy JN, Meena RA, Dunlap NE, Jain D, Riley EC, Quillo AR, Dragun AE. Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer. Clin Breast Cancer 2015;15:135-42. [PMID: 25454741 DOI: 10.1016/j.clbc.2014.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
617 Bertagnolli MM, Canetta R, Nass SJ. Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century". Oncologist 2014;19:1179-85. [PMID: 25326161 DOI: 10.1634/theoncologist.2014-0240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
618 Zhang WZ, Chen JZ, Li DR, Chen ZJ, Guo H, Zhuang TT, Li DS, Zhou MZ, Chen CZ. Simultaneous modulated accelerated radiation therapy for esophageal cancer: A feasibility study. World J Gastroenterol 2014; 20(38): 13973-13980 [PMID: 25320535 DOI: 10.3748/wjg.v20.i38.13973] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
619 Jeong Y, Kim JH. WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. Gastrointestinal Intervention 2014. [DOI: 10.1016/j.gii.2014.09.003] [Reference Citation Analysis]
620 Hayashi Y, Nishida T, Tsujii M, Tsutsui S, Yamamoto K, Isohashi F, Yamasaki M, Miyata H, Kato M, Yamada T. Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma. BMC Cancer. 2014;14:706. [PMID: 25253238 DOI: 10.1186/1471-2407-14-706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
621 Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32:3400-5. [PMID: 25225435 DOI: 10.1200/JCO.2014.56.7156] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
622 Fujinaka Y, Morita M, Ohga T, Kakeji Y, Yano T, Maehara Y. Definitive chemoradiotherapy and salvage esophagectomy for esophageal cancer associated with multiple lung metastases: a case report. Int Surg 2014;99:640-4. [PMID: 25216435 DOI: 10.9738/INTSURG-D-13-00123.1] [Reference Citation Analysis]
623 Foley K, Lewis W, Fielding P, Karran A, Chan D, Blake P, Roberts S. N-staging of oesophageal and junctional carcinoma: Is there still a role for EUS in patients staged N0 at PET/CT? Clinical Radiology 2014;69:959-64. [DOI: 10.1016/j.crad.2014.04.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
624 Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191. [PMID: 25175056 DOI: 10.1186/1748-717X-9-191] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
625 Liu N, Liu S, Xiang C, Cong N, Wang B, Zhou B, Zhang B, Li Y, Wang Y, Yuan S. Radioactive Self-Expanding Stents Give Superior Palliation in Patients With Unresectable Cancer of the Esophagus but Should Be Used With Caution if They Have Had Prior Radiotherapy. The Annals of Thoracic Surgery 2014;98:521-6. [DOI: 10.1016/j.athoracsur.2014.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
626 Ishikawa K, Nakamatsu K, Shiraishi O, Yasuda T, Nishimura Y. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. Int J Clin Oncol 2015;20:531-7. [PMID: 25073955 DOI: 10.1007/s10147-014-0736-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
627 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
628 Gupta A, Roy S, Majumdar A, Hazra A, Mallik C. A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer. Indian J Med Paediatr Oncol 2014;35:54-9. [PMID: 25006285 DOI: 10.4103/0971-5851.133722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
629 Wilson JM, Partridge M, Hawkins M. The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. Clin Oncol (R Coll Radiol) 2014;26:581-96. [PMID: 24998430 DOI: 10.1016/j.clon.2014.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
630 Lloyd S, Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol 2014;5:156-65. [PMID: 24982764 DOI: 10.3978/j.issn.2078-6891.2014.033] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
631 Moremen JR, Skopelja EN, Ceppa DP. The role of induction therapy. J Thorac Dis 2014;6 Suppl 3:S309-13. [PMID: 24876935 DOI: 10.3978/j.issn.2072-1439.2014.03.10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
632 D’Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis. 2014;6 Suppl 2:S253-S264. [PMID: 24868443 DOI: 10.3978/j.issn.2072-1439.2014.04.16] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
633 Hofstetter WL. Salvage esophagectomy. J Thorac Dis 2014;6 Suppl 3:S341-9. [PMID: 24876940 DOI: 10.3978/j.issn.2072-1439.2014.03.29] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
634 Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical esophageal cancer: a population-based study. Head Neck. 2015;37:808-814. [PMID: 24616217 DOI: 10.1002/hed.23678] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
635 Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014;86:336-339. [PMID: 24925190 DOI: 10.1159/000360703] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
636 Boggs DH, Tarabolous C, Morris CG, Hanna A, Burrows W, Horiba N, Suntharalingam M. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer: Trimodality therapy for esophageal cancer. Dis Esophagus 2015;28:619-25. [DOI: 10.1111/dote.12243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
637 Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W; Kitasato Digestive Disease and Oncology Group. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89:872-879. [PMID: 24867539 DOI: 10.1016/j.ijrobp.2014.03.030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
638 Liu H, Wang Q, Wan X, Jia X, Liu B, Wang CK. Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: Long-term treatment results. Brachytherapy. 2014;13:514-521. [PMID: 24818780 DOI: 10.1016/j.brachy.2014.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
639 Lu X, Wu H, Wang J, Chen Y, Xu J. Factors affecting long-term survival in elderly patients undergoing radiotherapy for esophageal carcinoma. Mol Clin Oncol 2014;2:571-4. [PMID: 24940497 DOI: 10.3892/mco.2014.285] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
640 Nagaraja V, Cox MR, Eslick GD. Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol 2014;5:119-26. [PMID: 24772340 DOI: 10.3978/j.issn.2078-6891.2014.007] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
641 Xu M, Huang H, Xiong Y, Peng B, Zhou Z, Wang D, Yang X. Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature. Oncol Lett 2014;8:291-4. [PMID: 24959263 DOI: 10.3892/ol.2014.2087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
642 Wallach JB, Rosenstein MM, Kalnicki S. Localized synchronous squamous cell carcinomas of the esophagus and hypopharynx treated with definitive concurrent chemoradiotherapy with a unified radiotherapy plan. Curr Oncol 2014;21:e354-7. [PMID: 24764720 DOI: 10.3747/co.21.1844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
643 Nguyen NP, Jang S, Vock J, Vinh-Hung V, Chi A, Vos P, Pugh J, Vo RA, Ceizyk M, Desai A. Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer. BMC Cancer. 2014;14:265. [PMID: 24742268 DOI: 10.1186/1471-2407-14-265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
644 Li WF, Zhang L, Li HY, Zheng SS, Zhao L. WISP-1 contributes to fractionated irradiation-induced radioresistance in esophageal carcinoma cell lines and mice. PLoS One 2014;9:e94751. [PMID: 24728101 DOI: 10.1371/journal.pone.0094751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
645 Fu C, Li B, Guo L, Li H, Huang W, Gong H, Sun M, Wang Z, Zhou T, Liu C. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2014;87:20130656. [PMID: 24666012 DOI: 10.1259/bjr.20130656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
646 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
647 Yu WW, Zhu ZF, Fu XL, Zhao KL, Mao JF, Wu KL, Yang HJ, Fan M, Zhao S, Welsh J. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol 2014;190:979-86. [PMID: 24609941 DOI: 10.1007/s00066-014-0636-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
648 Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol 2014;140:867-72. [DOI: 10.1007/s00432-014-1615-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
649 Zhang X, Li M, Meng X, Kong L, Zhang Y, Wei G, Zhang X, Shi F, Hu M, Zhang G. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2014;9:64. [PMID: 24571804 DOI: 10.1186/1748-717X-9-64] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
650 Karran A, Blake P, Chan D, Reid TD, Davies IL, Kelly M, Roberts SA, Crosby T, Lewis WG. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg 2014;101:502-10. [PMID: 24615406 DOI: 10.1002/bjs.9437] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
651 Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14. [PMID: 24556041 DOI: 10.1016/S1470-2045(14)70028-2] [Cited by in Crossref: 207] [Cited by in F6Publishing: 204] [Article Influence: 25.9] [Reference Citation Analysis]
652 Cellini F, Morganti AG, Di Matteo FM, Mattiucci GC, Valentini V. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol 2014;9:45. [PMID: 24499595 DOI: 10.1186/1748-717X-9-45] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
653 Honing J, Smit JK, Muijs CT, Burgerhof JGM, de Groot JW, Paardekooper G, Muller K, Woutersen D, Legdeur MJC, Fiets WE, Slot A, Beukema JC, Plukker JTM, Hospers GAP. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25:638-43. [PMID: 24492674 DOI: 10.1093/annonc/mdt589] [Cited by in Crossref: 63] [Cited by in F6Publishing: 78] [Article Influence: 7.9] [Reference Citation Analysis]
654 Haj Mohammad N, Hulshof MC, Bergman JJ, Geijsen D, Wilmink JW, van Berge Henegouwen MI, van Laarhoven HW. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer 2014;14:56. [PMID: 24485047 DOI: 10.1186/1471-2407-14-56] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
655 Main BG, Strong S, McNair AG, Falk SJ, Crosby T, Blazeby JM. Reporting outcomes of definitive radiation-based treatment for esophageal cancer: a review of the literature. Dis Esophagus 2015;28:156-63. [PMID: 24438540 DOI: 10.1111/dote.12168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
656 Schilsky RL. Wither the Cooperative Groups? JCO 2014;32:251-4. [DOI: 10.1200/jco.2013.52.0288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
657 Wang S, Tachimori Y, Hokamura N, Igaki H, Nakazato H, Kishino T. Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy. J Thorac Cardiovasc Surg 2014;147:1805-11. [PMID: 24521950 DOI: 10.1016/j.jtcvs.2013.12.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
658 Ku GY, Ilson DH. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 2014;8:1953-64. [DOI: 10.1586/14737140.8.12.1953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
659 Forde PM, Kelly RJ. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. J Thorac Oncol. 2013;8:673-684. [PMID: 23591158 DOI: 10.1097/jto.0b013e31828b5172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
660 Li M, Lin ZX. Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases. Thorac Cancer 2014;5:25-30. [PMID: 26766968 DOI: 10.1111/1759-7714.12047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
661 Lu X, Wu H, Wang J, Xu J. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged ≥75 years. Mol Clin Oncol 2014;2:297-301. [PMID: 24649350 DOI: 10.3892/mco.2013.235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
662 Kim DE, Kim UJ, Choi WY, Kim MY, Kim SH, Kim MJ, Shim HJ, Hwang JE, Bae WK, Chung IJ, Nam TK, Na KJ, Cho SH. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat 2013;45:276-84. [PMID: 24454000 DOI: 10.4143/crt.2013.45.4.276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
663 Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol 2013; 19(48): 9447-9452 [PMID: 24409075 DOI: 10.3748/wjg.v19.i48.9447] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
664 Song Y, Liang Y, Zang R, Hu L, Zhu S. Application of serial section method to determine the radiotherapy target volume for esophageal squamous carcinoma. Cell Biochem Biophys. 2013;66:351-356. [PMID: 23325307 DOI: 10.1007/s12013-012-9473-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
665 Xu HY, DU ZD, Zhou L, Yu M, Ding ZY, Lu Y. Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. Oncol Lett 2014;7:260-6. [PMID: 24348860 DOI: 10.3892/ol.2013.1694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
666 Markar SR, Karthikesalingam A, Penna M, Low DE. Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol 2014;21:922-31. [PMID: 24212722 DOI: 10.1245/s10434-013-3364-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
667 Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodríguez R, Zheng J, Wang L. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. Onco Targets Ther 2013;6:1589-96. [PMID: 24235844 DOI: 10.2147/OTT.S50945] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
668 Hoppo T, Jobe BA. Personalizing Therapy for Esophageal Cancer Patients. Thoracic Surgery Clinics 2013;23:471-8. [DOI: 10.1016/j.thorsurg.2013.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
669 Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for Esophageal Cancer. Thoracic Surgery Clinics 2013;23:551-8. [DOI: 10.1016/j.thorsurg.2013.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
670 Lin C, Huang W, Jen Y, Chen C, Su Y, Chao H, Lin C. Dosimetric and efficiency comparison of high-dose radiotherapy for esophageal cancer: volumetric modulated arc therapy versus fixed-field intensity-modulated radiotherapy: VMAT versus IMRT for esophageal cancer. Dis Esophagus 2014;27:585-90. [DOI: 10.1111/dote.12144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
671 Adenis A, Tresch E, Dewas S, Romano O, Messager M, Amela E, Clisant S, Kramar A, Mariette C, Mirabel X. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013;13:413. [PMID: 24010566 DOI: 10.1186/1471-2407-13-413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
672 Morita M, Saeki H, Ito S, Kimura Y, Yamashita N, Ando K, Hiyoshi Y, Tokunaga E, Oki E, Ikeda T, Yoshida S, Nakashima T, Maehara Y. Surgical strategies for esophageal cancer associated with head and neck cancer. Surg Today 2014;44:1603-10. [PMID: 23989943 DOI: 10.1007/s00595-013-0713-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
673 Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol 2013;24:2854-9. [PMID: 23994746 DOI: 10.1093/annonc/mdt340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
674 Tseng YD, Wo JY, Ancukiewicz M, Adams J, Depauw N, Mamon HJ, Hong TS. Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer. J Radiat Oncol 2013;2:427-34. [DOI: 10.1007/s13566-013-0114-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
675 Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, Hanada T, Shiraishi Y, Kitagawa Y, Fukuda K. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 2013;87:487-93. [PMID: 23968770 DOI: 10.1016/j.ijrobp.2013.07.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
676 Saeki H, Morita M, Tsuda Y, Hidaka G, Kasagi Y, Kawano H, Otsu H, Ando K, Kimura Y, Oki E, Kusumoto T, Maehara Y. Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. Ann Surg Oncol 2013;20:4267-73. [DOI: 10.1245/s10434-013-3192-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
677 Worni M, Castleberry AW, Gloor B, Pietrobon R, Haney JC, D'Amico TA, Akushevich I, Berry MF. Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. Dis Esophagus 2014;27:662-9. [PMID: 23937253 DOI: 10.1111/dote.12123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
678 Takeuchi M, Kobayashi M, Hashimoto S, Mizuno K, Kawaguchi G, Sasamoto R, Aoyama H, Aoyagi Y. Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Scand J Gastroenterol. 2013;48:1095-1101. [PMID: 23906093 DOI: 10.3109/00365521.2013.822092] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
679 Cheng J, Kong L, Huang W, Li B, Li H, Wang Z, Zhang J, Zhou T, Sun H. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases. J Thorac Oncol 2013;8:359-65. [PMID: 23263689 DOI: 10.1097/JTO.0b013e31827e1f6d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
680 Zhu H, Huo X, Chen L, Wang H, Yu H. Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer. Mol Clin Oncol 2013;1:1009-12. [PMID: 24649285 DOI: 10.3892/mco.2013.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
681 Powathil GG, Adamson DJ, Chaplain MA. Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model. PLoS Comput Biol 2013;9:e1003120. [PMID: 23874170 DOI: 10.1371/journal.pcbi.1003120] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
682 Francis SR, Anker CJ, Wang B, Williams GV, Cox K, Adler DG, Shrieve DC, Salter BJ. Self-expanding stent effects on radiation dosimetry in esophageal cancer. J Appl Clin Med Phys 2013;14:4218. [PMID: 23835387 DOI: 10.1120/jacmp.v14i4.4218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
683 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
684 Chi CW, Chen CC, Chen YJ. Therapeutic and radiosensitizing effects of armillaridin on human esophageal cancer cells. Evid Based Complement Alternat Med 2013;2013:459271. [PMID: 23864890 DOI: 10.1155/2013/459271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
685 Wang YC, Chen SW, Chien CR, Hsieh TC, Yu CY, Kuo YC, Yang SN, Kao CH, Liang JA. Radiotherapy for esophageal cancer using simultaneous integrated boost techniques: dosimetric comparison of helical TomoTherapy, Volumetric-modulated Arc Therapy (RapidArc) and dynamic intensity-modulated radiotherapy. Technol Cancer Res Treat 2013;12:485-91. [PMID: 23745789 DOI: 10.7785/tcrt.2012.500348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
686 Rice TW. Esophageal Nightmare: Cancer Recurrence After Definitive Chemoradiation. Is Salvage Esophagectomy Possible? Seminars in Thoracic and Cardiovascular Surgery 2013;25:83-6. [DOI: 10.1053/j.semtcvs.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
687 Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 2013;17:1359-69. [PMID: 23715646 DOI: 10.1007/s11605-013-2223-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
688 Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, M'vondo CM, Olivier P, Faure G, Itti E, Diana C, Houzard C, Mornex F, Di Fiore F, Vera P. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013;40:1345-55. [PMID: 23715903 DOI: 10.1007/s00259-013-2450-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
689 Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Lai ST, Jiang GL, Zhao KL. Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol 2014;19:297-302. [PMID: 23690261 DOI: 10.1007/s10147-013-0564-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
690 Monjazeb AM, Blackstock AW. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Semin Radiat Oncol. 2013;23:60-73. [PMID: 23207048 DOI: 10.1016/j.semradonc.2012.09.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
691 Liu J, Yue J, Xing L, Yu J. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med. 2013;7:172-179. [PMID: 23681891 DOI: 10.1007/s11684-013-0268-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
692 Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy 2013;14:1345-54. [DOI: 10.1517/14656566.2013.801454] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
693 Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Salze P, Noël G. [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study]. Cancer Radiother 2013;17:221-8. [PMID: 23684111 DOI: 10.1016/j.canrad.2013.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6]